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Abstract 
 
 
This thesis describes studies surrounding a ligand-gated ion channel (LGIC): the 
serotonin type 3A receptor (5-HT3AR).  Structure-function experiments using unnatural 
amino acid mutagenesis are described, as well as experiments on the methodology of 
unnatural amino acid mutagenesis.  Chapter 1 introduces LGICs, experimental methods, 
and an overview of the unnatural amino acid mutagenesis. 
In Chapter 2, the binding orientation of the clinically available drugs ondansetron and 
granisetron within 5-HT3A is determined through a combination of unnatural amino acid 
mutagenesis and an inhibition based assay.  A cation-π interaction is found for both 
ondansetron and granisetron with a specific tryptophan residue (Trp183, TrpB) of the 
mouse 5-HT3AR, which establishes a binding orientation for these drugs. 
In Chapter 3, further studies were performed with ondansetron and granisetron with 
5-HT3A.  The primary determinant of binding for these drugs was determined to not 
include interactions with a specific tyrosine residue (Tyr234, TyrC2).  In completing 
these studies, evidence supporting a cation-π interaction of a synthetic agonist, meta-
chlorophenylbiguanide, was found with TyrC2. 
In Chapter 4, a direct chemical acylation strategy was implemented to prepare full-
length suppressor tRNA mediated by lanthanum(III) and amino acid phosphate esters.  
The derived aminoacyl-tRNA is shown to be translationally competent in Xenopus 
oocytes. 
Appendix A.1 gives details of a pharmacological method for determining the 
equilibrium dissociation constant, KB, of a competitive antagonist with a receptor, known 
as Schild analysis.  Appendix A.2 describes an examination of the inhibitory activity of 
 vi 
new chemical analogs of the 5-HT3A antagonist ondansetron.  Appendix A.3 reports an 
organic synthesis of an intermediate for a new unnatural amino acid.  Appendix A.4 
covers an additional methodological examination for the preparation of amino-acyl 
tRNA.  
 vii 
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Chapter 1 
 
A Molecular-Scale Approach to Neuroscience 
 
1.1 INTRODUCTION 
Neuroscience is one of the most interdisciplinary fields of science, and for good 
reason: the brain is the most complex structure on earth.1  The open question of 
understanding of the brain is approached at many levels, from the broadly macroscopic 
view of psychology and medicine, all the way down to the molecular studies of 
biochemists and chemists.  Each approach has its own merits and revelations, but it is the 
molecular approach that this thesis covers. In order to add context to the following 
chapters of this thesis, information regarding receptors and the experimental techniques 
used are covered here. 
Communication that occurs in the brain can be viewed as both electrical and chemical 
(Figure 1.1).  A signal, the action potential, is an electrical impulse that propagates down 
the axon of a neuron.  A second neuron slated to receive this signal is not in electrical 
contact with the sender; the cells are separated at a junction called the synapse.   For the 
neurons to communicate, the electrical signal is converted to a chemical signal.  
Depolarization of the presynaptic neuron results in the release of small-molecule 
neurotransmitters into the synaptic cleft, which then passively diffuse to the postsynaptic 
neuron.  These small-molecule neurotransmitters then bind to receptor proteins on the 
membrane of the postsynaptic neuron.  Depending on the nature of the neurotransmitter 
and the receptor, the electrical signal is regenerated and a new action potential propagates 
in the postsynaptic neuron. 
 2 
 
Figure 1.1.  A cartoon representing a pair of neurons (left) and a synapse (right).  The top neuron 
represents the presynaptic cell, and the bottom cell represents the postsynaptic cell.  Yellow lightning bolts 
represent an action potential.  The action potential in the presynaptic cell triggers the release of small-
molecule neurotransmitters (blue dots) into the synaptic cleft.  Passive diffusion of the neurotransmitters 
results in binding to receptors on the postsynaptic cell.  The triggering of postsynaptic receptors can cause a 
new action potential to form in the postsynaptic cell. 
 
 
The binding of the neurotransmitter to the receptor protein is a molecular event 
governed by non-covalent interactions.  After the binding event, a cascade of 
conformational changes within the receptor protein occurs, which are also governed by 
non-covalent interactions.  What then, is the nature of these non-covalent interactions?  A 
question such as this is tackled in Chapter 2 regarding ligand-receptor interactions.  In the 
Dougherty group, similar molecular-scale questions have been asked and answered many 
times over.2  Understanding these receptors is more than just scientific curiosity: these 
receptors are central to human health, and their dysfunction plays roles in diseases such 
as epilepsy and schizophrenia.3,4 
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The receptors covered in this thesis are ligand-gated ion channels (LGICs).  LGICs 
allow the passage of ions across a cell membrane in response to the binding of a ligand.  
The Cys-loop superfamily of LGICs includes the nicotinic acetylcholine receptor 
(nAChR), serotonin (5-hydroxytryptamine) type 3 receptor (5-HT3R), γ-aminobutyric 
acid receptor (GABA), and glycine receptor (GlyR).5  The 5-HT3R is the subject of study 
in Chapter 2 and  Chapter 3.  Subtypes of the nAChR make an appearance in Chapter 4.  
 
Figure 1.2.  A cartoon representing a Cys-loop receptor.  Left:  General dimensions and a representation of 
the pentameric nature of Cys-loop receptors.  Right:  Topology of a Cys-loop receptor, with a general 
indication of the ligand binding site and a disulfide linkage to form the eponymous “Cys-loop.” 
  
 
The strategy used for studying these receptors in this thesis is through structure-
function experiments: a structural change is made and its effect on function is 
determined.  While such experiments can be performed without prior structural 
information, design of experiments certainly benefits if some structural information is 
known.  In all cases, Cys-loop receptors form an ion pore by the assembly of five 
subunits (Figure 1.2).  There is a large, extracellular N-terminal domain that is the site of 
neurotransmitter binding, followed by four membrane-spanning α-helices, and finally an 
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extracellular C-terminus.  Early structural information came from cryo-electron 
microscopy (cryo-EM) images of receptors from the electric organ of the Torpedo ray.6  
Other insights came from X-ray structures of a soluble protein found in the snail 
cholinergic synapse, which is homologous to the extracellular domain of Cys-loop 
receptors.7  Finally, an X-ray structure of the glutamate-gated chloride channel from C. 
elegans (GluCl) gave high resolution information to complement the cryo-EM images 
(Figure 1.3).8 
 
Figure 1.3.  Representative structures of Cys-loop receptors.  Protein Data Bank codes for each structure 
shown. 
 
  
This structural information, while useful, does not provide functional insight into the 
Cys-loop receptors.  For that, a functional assay, electrophysiology, is used.  The mRNA 
coding for the appropriate subunits of the LGIC of interest is microinjected into the 
oocyte of Xenopus laevis, which is a large (~ 1 mm) and mostly dormant living cell 
(Figure 1.4a).  After mRNA injection, Xenopus oocytes synthesize the LGIC subunit(s), 
out!
in! membrane'
Crystal'structure'of'GluCl'
(a'Cys3loop'receptor)'
Cryo3EM'structure'of'nAChR' Crystal'structure'of'
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assemble them into receptors, and transport them to the cell surface.  From there, a two-
electrode whole-cell voltage clamp experiment, where the potential across the cell 
membrane is held constant during the experiment, can be performed.  In this setup, the 
membrane potential measured is by one electrode.  An activating ligand, called an 
agonist, is washed over the cell surface, resulting in the opening of a population of 
receptors.  The flow of ions across the cell surface is exactly equivalent to an electric 
current, and so the second electrode maintains the cell potential by applying an opposing 
current, which is readily measured.  By applying increasing concentrations of agonist to 
the oocyte, an increase in signal is detected (Figure 1.4b).  Plotting these concentration-
response data in a semi-log plot and fitting the data to the Hill equation allows one to 
determine a parameter called the EC50 (Figure 1.4c-d).  The EC50 is the concentration of 
agonist required to elicit half-maximal current, and is reflective of channel function. 
 
Figure 1.4.  Aspects of the functional assay.  (a) A Xenopus oocyte.  (b)  Representative increases in 
measured current in response to increases in the concentration of applied agonist.  (c)  The Hill equation.  
(d) A concentration-response curve, and the location of the EC50 parameter. 
 
 
With a functional assay in hand, molecular-scale insight is achieved through structural 
changes to the receptor.  This is done through mutagenesis.  Individual amino acids 
1"mm"
Xenopus oocyte 
(a)" (b)"
(c)"
(d)"
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within the protein are substituted for other amino acids by changing the mRNA code.  In 
its most basic form, this only allows the substitution of an amino acid for one of the 20 
naturally occurring amino acids.  To obtain truly chemical-scale information, a technique 
called nonsense suppression is used to install unnatural amino acids, which allows for 
extremely subtle structural changes.9  In this technique, at the site of interest is mutated to 
a UAG codon (called amber), which is normally interpreted at a “stop” codon.  A 
suppressor tRNA bearing the desired unnatural amino acid, which recognizes the amber 
codon, is co-injected into the Xenopus oocyte (Figure 1.5).  In this manner, the unnatural 
amino acid is installed site-specifically during protein translation.  An important feature 
of the suppressor tRNA is a property called orthogonality: after delivering its amino acid 
payload, the amino acid synthetases in the Xenopus oocyte do not recharge the tRNA 
with another amino acid.  The orthogonality of the tRNAs used in nonsense suppression 
are not perfect, and so controls using uncharged tRNA should be performed.  As the 
suppressor tRNA does not get recharged, it is a limiting reagent in this process.  Chapter 
4 explores the methodology for preparing this important component. 
Once a structural change is made to a receptor, the functional effect is then measured.  
A concentration-response plot is constructed for the mutant receptor and the EC50 value is 
determined.  If the structural change was detrimental to the function of the receptor (for 
the agonist used), a rightward shift in the concentration-response curve is seen, with a 
correspondingly higher EC50 value (Figure 1.6a).  A larger EC50 is referred to as a “loss 
of function,” while the opposite case (a leftward curve shift and lower EC50) is referred to 
as a “gain of function.”  In this manner, functional changes with respect to activating 
ligands (agonists) are directly determined.  Another class of ligands, antagonists, inhibits 
 7 
 
Figure 1.5.  Overview of expression of receptors bearing unnatural amino acids in Xenopus oocytes.  (1)  
The mRNA for the receptor containing a stop codon at the site of interest and (2) the suppressor tRNA 
bearing the unnatural amino acid are (3) co-injected into the Xenopus oocyte.  (4) The translational 
machinery synthesizes the receptor and inserts the unnatural amino acid into the peptide chain, and after 
transport to the cell surface, (5) the receptors are probed by electrophysiology. 
 
 
channel function.  Structural changes to the receptor can also affect the ability of an 
antagonist to inhibit the receptor, but this is not determined through an EC50 
measurement.  As measureable signal is only obtained in the presence of an agonist, an 
assay involving application of both agonist and antagonist to the receptor is needed.  
Chapter 2 discusses this measurement and its parameter, the IC50.  The IC50 is the 
concentration needed to achieve half-maximal inhibition of the signal (Figure 1.6b).  In a 
manner similar to the EC50, the ability of an antagonist to inhibit a receptor with respect 
to a structural change is determined through increases or decreases in the IC50 value. 
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Figure 1.6.  Idealized concentration-response curves showing a shift in response as a result of a structural 
change in the receptor.  (a) Shifts activation ability of an agonist.  (b) Shifts in inhibition ability of an 
antagonist. 
 
 
With the discussion thus far regarding structure-function studies of receptors, the case 
has not been made as to the need for unnatural amino acid mutagenesis.  A particular 
non-covalent interaction, the cation-π interaction, is well suited for study by unnatural 
amino acid mutagenesis.  A cation-π is a mainly electrostatic interaction between a cation 
and the π face of an aromatic ring (Figure 1.7a).10,11  With conventional mutagenesis, 
there are only three aromatic amino acids: tryptophan, tyrosine, and phenylalanine.  
Probing for a cation-π interaction requires more subtle probes than these three amino 
acids can provide.  For example, in mutating a tryptophan to a phenylalanine, there is a 
change in the cation-π binding ability, but there are also steric perturbations that would 
complicate the analysis.  With unnatural amino acid mutagenesis, a much more subtle 
change, such as fluorination of the aromatic ring, can be used to probe for this interaction.  
The steric perturbation of the addition of a fluorine atom to an aromatic ring is minimal, 
but the electronegative nature of fluorine decreases the cation-π binding ability of the ring 
system.  This effect is additive, and so additional fluorine atoms results in further 
decreases in ring cation-π binding ability (Figure 1.7b).  When the cation-π binding 
(a)$ (b)$
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ability of an aromatic ring is plotted against changes in channel function, information as 
to the existence of a cation-π interaction can be obtained.  This strategy is employed in 
Chapter 2 and Chapter 3. 
 
Figure 7.  The cation-π interaction. (a) A representation of a Na+ cation binding to the face of benzene. (b) 
Ab initio calculated cation-π binding energies of indoles and fluorinated indoles.12 
 
 
1.2 SUMMARY 
The field of neuroscience benefits from the contributions of a broad range of 
disciplines.  The molecular-scale approach taken in this thesis utilizes a variety of 
techniques, including organic synthesis, molecular biology, and electrophysiology.  
Chapter 2 probes the interaction of the antagonists granisetron and ondansetron with the 
Cys-loop receptor 5-HT3A.  Chapter 3 expands upon the work of Chapter 2 with further 
examination of antagonist interactions, as well as the synthetic agonist meta-
chlorophenylbiguanide.  Chapter 4 examines a chemical methodology for the preparation 
of charged suppressor tRNA.  There are four appendices which cover: (1) a methodology 
for measuring competitive antagonist/receptor affinities using pharmacology; (2) an 
examination of the inhibitory activity of new chemical analogs of the 5-HT3A antagonist 
ondansetron; (3) the organic synthesis of an intermediate for a new unnatural amino acid; 
and (4) an additional methodological examination of the preparation of charged 
suppressor tRNA. 
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Chapter 2 
 
Ondansetron and Granisetron Binding Orientation in the 5-HT3 
Receptor Determined by Unnatural Amino Acid Mutagenesis. 
 
Noah H. Duffy†, Henry A. Lester‡, Dennis A. Dougherty† 
†Division of Chemistry and Chemical Engineering and ‡Division of Biology, California 
Institute of Technology, Pasadena, California 91125 
 
2.1 ABSTRACT 
The serotonin type 3 receptor (5-HT3R) is a ligand-gated ion channel that mediates fast 
synaptic transmission in the central and peripheral nervous systems.  The 5-HT3R is a 
therapeutic target, and the clinically available drugs ondansetron and granisetron inhibit 
receptor activity.  Their inhibitory action is through competitive binding to the native 
ligand binding site, although the binding orientation of the drugs at the receptor has been 
a matter of debate.  Here we heterologously express mouse 5-HT3A receptors in Xenopus 
oocytes, and use unnatural amino acid mutagenesis to establish a cation-π interaction for 
both ondansetron and granisetron to tryptophan 183 in the ligand binding pocket.  This 
cation-π interaction establishes a binding orientation for both ondansetron and 
granisetron within the binding pocket. 
 
 
 
 
 
 
 
 
 
 
Reproduced with permission from Duffy, N. H.; Lester, H. A.; Dougherty, D. A., Ondansetron and 
Granisetron Binding Orientation in the 5-HT3 Receptor Determined by Unnatural Amino Acid 
Mutagenesis. ACS Chem. Biol. 2012, 7, 1738-1745. Copyright 2012 American Chemical Society. 
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2.2 INTRODUCTION 
The serotonin type 3 receptor (5-HT3R)1,2 is a ligand-gated ion channel in the Cys-loop 
(pentameric) family of receptors, which also includes GABAA, glycine, and nicotinic 
acetylcholine (nACh) receptors.3  The 5-HT3 receptor is a cation selective channel found 
in the central and peripheral nervous systems.  Conduction occurs through a central pore, 
formed by the pseudo-symmetric assembly of five subunits (Figure 2.1).  There are five 
known 5-HT3R subunits (A – E),4 with the best characterized receptors being the 
homomeric 5-HT3A receptor (5-HT3AR) and the heteromeric 5-HT3AB receptors.5 
 
 
Figure 2.1.  Basic layout of a Cys-loop (pentameric) receptor. The structure is that of the GluCl α subunit6 
(pdb 3RIF). Left: The full receptor, with two subunits highlighted; one (blue) contributes principal agonist 
binding site residues, found on loops A (red), B (green), and C (blue).  The complementary subunit (black) 
contributes loops D (purple), E (orange), and F (yellow). The α-helical region corresponds to the 
transmembrane domain; the region above it is extracellular. Right: Detail of agonist binding site, noting 
approximate locations of key residues considered here. 
 
The 5-HT3 receptor has been validated as a therapeutic target—antagonists are 
currently used to control chemotherapy-induced nausea, as well as to treat irritable bowel 
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syndrome.7,8  Beyond current clinical uses, there is evidence that compounds targeting the 
5-HT3 receptor could be useful for the treatment of a variety of disorders including 
schizophrenia and substance abuse, as well as management of pain associated with, for 
example, fibromyalgia.  Prototype antagonists of the 5-HT3 receptor are ondansetron 
(Zofran®) and granisetron (Kytril®) (Figure 2.2a). 
 
 
Figure 2.2.  Chemical structures of drugs and amino acids used in this study.  (a) 5-HT3A receptor 
antagonists.  (b) 5-HT3A receptor agonists. (c) Tryptophan analogs. 
 
There is no high-resolution structure of the 5-HT3 receptor.  There is, however, 
structural information from a number of sources, including cryoelectron microscopy 
images of the nACh receptor,9 high resolution structures of the homologous acetylcholine 
binding protein,10 and the recently published x-ray structure of the glutamate-gated 
chloride channel from C. elegans, GluCl.6  These data, along with homology modeling 
and biochemical studies, have provided a putative binding site for 5-HT3 antagonists that 
coincides with the binding site of the native agonist, serotonin (5-HT, Figure 2.2b).  This 
binding site is formed by a series of β-strands and connecting loops (labeled A-F), with 
loops A-C contributed by the “principal” subunit and β-strands D-F contributed by the 
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“complementary” subunit (Figure 2.1).  Docking studies using homology models have 
found multiple energetically favorable poses of the antagonist granisetron within this 
binding site, and the orientation of the drug and the identities of the interacting residues 
are not constant across poses.11-14  For example, Thompson et. al. reported two classes of 
poses of granisetron.13  In one class, the cationic ammonium was oriented between 
Trp183 (loop B) and Tyr234 (loop C), while the aromatic indazole was oriented between 
Trp90 (β-strand D) and Phe226 (loop C).  In the second class of poses, this orientation 
was reversed, with the cationic ammonium towards Trp90 and Phe226.  Experimentally, 
both Trp183 and Trp90 have been established to be important for granisetron binding.  In 
other experimental work, Yan and White found that Trp90 is important for both 
ondansetron and granisetron binding, and they interpreted their results as providing 
evidence that the cationic ammonium of granisetron was oriented towards Trp90.14 
The accepted pharmacophore model for 5-HT3R includes an amine group on the 
ligand.  Past studies in our laboratory have established the primary amine of 5-HT to 
make a cation-π interaction with a conserved tryptophan residue on loop B (Trp183).15  
Mutation of Trp183 (as well as Trp90, Glu129 (loop A), and Tyr234) to alanine abolishes 
binding of [3H]granisetron.13 Taken together, these results identify Trp183 as a prime 
candidate for more detailed studies.  Moreover, the docking studies of Thompson et. al. 
provide us with testable guidelines as to other possible interactions; specifically, with 
Trp90.13  In the present work, we set out to better understand the binding of the high 
affinity antagonistic drugs ondansetron and granisetron to the 5-HT3AR.  The cationic 
center of granisetron is a tertiary ammonium ion in a granatane moiety (pKa = 9.6), but 
ondansetron has a structurally distinct N-akylimidazolium moiety (pKa = 7.4).16  We 
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sought to determine if this structural difference leads to different binding orientations for 
the two drugs. 
2.3 RESULTS AND DISCUSSION 
2.3.1 Ondansetron and Granisetron Schild Analysis.  In examining the interaction of a 
competitive antagonist with a receptor, equilibrium dissociation constants, Kb, provide 
the most direct indicator of binding interactions.17  Previous reports have indicated that 
granisetron and ondansetron act competitively with 5-HT at the 5-HT3AR.2,18  Both 
antagonists bind reversibly, in that after a several minute washout of either ondansetron 
or granisetron, agonist responses recover completely.  Previous studies have established 
dissociation rate constants of 0.58 min-1 for ondansetron, and 0.13 min-1 for granisetron,19 
consistent with our observations.  It has also been shown that granisetron and 
ondansetron directly compete with each other for the same binding site.19  We attempted 
to determine Kb for ondansetron and granisetron using Schild (dose-ratio) analysis;17 this 
requires measurements of dose-response relationships (Figure 2.3).  Schild analysis of 
ondansetron applied to preparations of rat vagus nerves gave parallel shifts, indicative of 
a competitive interaction, but efforts to perform similar studies with granisetron were not 
successful.20  As shown in Figure 2.3, during our standard 15 second agonist application 
(see Methods), the inhibition by ondansetron and granisetron was insurmountable by 
5-HT—full receptor activity could not be restored even with high concentrations of 5-HT.  
We attribute the insurmountable inhibition to the slow off rates. The granisetron data are 
better behaved than the ondansetron data, but in either case we face a requirement of 
agonist applications several minutes in duration.  However, the 5-HT3AR desensitizes on 
this time scale before full equilibrium is achieved.  Thus, for the high-affinity 5-HT3AR 
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antagonists ondansetron and granisetron, determination of true Kb by functional 
measurements is not possible. 
 
Figure 2.3.  Dose-response curves of wild-type 5-HT3A receptor.  Responses to 5-HT with increasing 
concentrations of (a) ondansetron, and (b) granisetron.  Data fit to the Hill equation.  Fit parameters (a) 
Mean maximal current: 8 ± 4 µA. [ondansetron] = 0 nM, EC50: 1.3 ± 0.2 µM, nH: 2.4 ± 0.6; [ondansetron] = 
0.64 nM, Imax: 63%, EC50: 1.1 ± 0.4 µM, nH: 2 ± 1; [ondansetron] = 4.5 nM, Imax = 61%, EC50: 9 ± 29 
µM, nH: 2 ± 8. (b) Mean maximal current: 9 ± 4 µA. [granisetron] = 0 nM, EC50: 1.5 ± 0.1 µM, nH: 2.0 ± 
0.1; [granisetron] = 0.6 nM, Imax: 25%, EC50: 0.7 ± 0.7 µM, nH: 2 ± 7; [granisetron] = 1.2 nM, Imax: 4%, 
EC50: 1 ± 1 µM, nH: 1 ± 2. 
   
Thus, the concentration required for 50% receptor inhibition (IC50) was the only viable 
functional measurement, and so modified procedures were developed to render IC50 
values a good direct measure of antagonist binding.  The IC50 measurement is taken in the 
context of multiple equilibria, including both agonist and antagonist binding/dissociation, 
conformational changes in the protein, and the “gating” equilibria between the open the 
closed states of the receptor.  We sought to reduce the contribution from changes in 
agonist potency, while retaining an index of antagonist potency.  When evaluating 
competitive antagonists, it is useful to consider more than one agonist, so that one can be 
sure that IC50 determinations are not distorted by agonist-receptor interactions.  To 
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determine IC50 values for ondansetron and granisetron, we studied both 5-HT and an 
additional agonist, meta-chlorophenylbiguanide (mCPBG, Figure 2.2b).21 
2.3.2 Agonist behavior at Trp183 and Trp90. The effective concentrations for 50% 
receptor activation (EC50) were determined for both the native agonist 5-HT, as well as 
the potent partial agonist mCPBG.  The EC50 values were also determined for a series of 
fluorinated tryptophan derivatives (Figure 2.2c) introduced by nonsense suppression at 
Trp183 (Table 2.1).  The EC50 values confirm the previously reported15 cation-π 
interaction for 5-HT at Trp183.  Interestingly, we have recently found that mCPBG does 
not respond to fluorination at Trp183 in the same manner as 5-HT,22 and the data of 
Table 2.1 produced for this work confirm that result. Detailed experiments and discussion 
concerning the activation of 5-HT3 receptors by mCPBG will be presented in a separate 
publication.22 For the present purposes, the key point is that mCPBG responds to 
fluorination at Trp183 differently than 5-HT. 
Table 2.1.  EC50 data for wild type and mutant 5-HT3AR in response to 5-HT or mCPBG. 
Agonist Mutation Na EC50 (µM)b Fold Shiftc Hilld 
5-HT Wild Type 25 1.6 ± 0.1 - 2.1 ± 0.2 
 W183F1W (5) 18 3.4 ± 0.2 2.2 2.0 ± 0.2 
 W183F2W (5,7) 11 18 ± 1 11 2.9 ± 0.2 
 W183F2W (4,7) 19 36 ± 2 23 2.2 ± 0.3 
 W183F3W (5,6,7) 10 250 ± 10 160 5 ± 1  W90F3W (5,6,7) 20 0.23 ± 0.01 1 / 6.8 2.0 ± 0.2 
 W90F4W (4,5,6,7) 29 0.64 ± 0.03 1 / 2.4 2.3 ± 0.2 mCPBG Wild Type 9 0.50 ± 0.02 - 2.2 ± 0.1 
 W183F1W (5) 14 5.8 ± 0.4 12 1.6 ± 0.1 
 W183F2W (5,7) 9 2.6 ± 0.1 5.3 1.8 ± 0.1 
 W183F2W (4,7) 19 0.34 ± 0.03 1 / 1.5 1.4 ± 0.1 
 W183F3W (5,6,7) 13 6.6 ± 0.2 13 2.6 ± 0.2 
 W183F4W (4,5,6,7) 14 8.4 ± 0.6 17 1.5 ± 0.1  W90F3W (5,6,7) 15 0.092± 0.004 1 / 5.4 3.2 ± 0.5 
 W90F4W (4,5,6,7) 7 0.20 ± 0.02 1 / 2.5 2.1 ± 0.3 
aNumber of oocytes averaged in EC50 determination.  bThe effective concentration for half-maximal 
receptor activation.  cEC50(mutant)/EC50(wild type).  dThe Hill coefficient, nH, as determined from fitting 
the Hill equation. 
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When the fluorinated tryptophans F3Trp and F4Trp were installed at Trp90, both 5-HT 
and mCPBG show a gain of function.  These data are consistent with no cation-π 
interaction for 5-HT or mCPBG with Trp90. 
2.3.3 Ondansetron and Granisetron at Trp183 and Trp90. An important aspect of the 
complex nature of measuring IC50 in receptors is the concentration of agonist used for 
receptor activation.  For a competitive interaction, a measured IC50 value will depend on 
the agonist concentration.17  In order to make meaningful comparisons of IC50 values 
across mutant receptors, the concentration of agonist used was kept at a constant value of 
twice EC50 .  The choice of a constant ratio of twice EC50 was made to ensure sufficient 
signal, even in cases of low receptor expression. We also emphasize that the series of 
mutations being introduced represents a much more subtle variation in structure than is 
possible with conventional mutagenesis.  This provides further confidence that no 
dramatic changes in receptor-antagonist interactions are occurring in the study. We also 
exploited the difference in the binding modes of 5-HT and mCPBG to control for 
possible artificial trends in IC50 measurements. 
Dose-response/inhibition relations were determined for ondansetron and granisetron, 
using both 5-HT and mCPBG as agonists, with representative voltage-clamp traces 
shown in Figure 2.4.  These measurements were performed on the wild type 5-HT3AR, as 
well as for a series of fluorinated tryptophan derivatives at Trp183. Agonist 
concentrations were 2 x EC50 for each agonist at each receptor, and data were fit to the 
Hill equation (Figure 2.4).  The resultant IC50 values are presented in Table 2.2.  
Inhibition data for F4Trp could not be gathered using 5-HT as the agonist, because of 
channel block by high concentrations of 5-HT. 
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Figure 2.4.  Representative voltage-clamp traces and dose-inhibition curves for antagonists for wild type 
and Trp183 mutant 5-HT3A receptors.  Representative traces for inhibition of (a) wild-type and (b) 
W183F3W receptors by increasing doses of granisetron.  Time of application and concentration noted by 
black bars.  Channels opened by addition of mCPBG (red bars) at (a) 1 µM and (b) 13 µM.  Hashes 
indicate wash times.  Ondansetron inhibition curves shown for receptors activated by (c) mCPBG, and (d) 
5-HT.  Granisetron inhibition curves shown for receptors activated by (e) mCPBG, and (f) 5-HT.  Data fit 
to the Hill equation; fit parameters (IC50 and nH) are in Table 2.2. 
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Table 2.2.  IC50 data for wild type and mutant 5-HT3AR for granisetron and ondansetron in response to 
5-HT or mCPBG. 
Antagonist Agonista Mutation Nb IC50 (nM)c Fold Shiftd Hille 
Granisetron 5-HT Wild Type 27 0.78 ± 0.04 - -1.4 ± 0.1 
  W183F1W (5) 17 2.9 ± 0.3 3.7 -1.4 ± 0.2 
  W183F2W (5,7) 14 100 ± 10 130 -1.7 ± 0.2 
  W183F2W (4,7) 11 3.4 ± 0.2 4.4 -1.6 ± 0.1 
  W183F3W (5,6,7) 9 61 ± 2 78 -1.6 ± 0.1   W90F3W (5,6,7) 11 0.20 ± 0.03 1 / 3.9 -1.1 ± 0.1 
  W90F4W (4,5,6,7) 12 0.64 ± 0.03 1 / 1.2 -1.8 ± 0.1 Granisetron mCPBG Wild Type 27 1.5 ± 0.1 - -1.5 ± 0.1 
  W183F1W (5) 8 3.3 ± 0.2 2.2 -1.4 ± 0.1 
  W183F2W (5,7) 16 140 ± 10 93 -1.5 ± 0.1 
  W183F2W (4,7) 13 2.4 ± 0.3 1.6 -1.3 ± 0.2 
  W183F3W (5,6,7) 9 41 ± 2 27 -1.2 ± 0.1 
  W183F4W (4,5,6,7) 14 110 ± 10 74 -0.9 ± 0.1   W90F3W (5,6,7) 7 0.20 ± 0.02 1 / 7.6 -1.2 ± 0.1 
  W90F4W (4,5,6,7) 9 0.38 ± 0.04 1 / 4 -1.3 ± 0.2 
Ondansetron 5-HT Wild Type 21 0.87 ± 0.04 - -1.6 ± 0.1 
  W183F1W (5) 16 6.2 ± 0.4 7.1 -1.5 ± 0.1 
  W183F2W (5,7) 11 140 ± 10 160 -2.2 ± 0.2   W183F2W (4,7) 9 67 ± 6 77 -1.7 ± 0.2 
  W183F3W (5,6,7) 9 160 ± 10 180 -1.8 ± 0.1   W90F3W (5,6,7) 13 0.40 ± 0.03 1 / 2.2 -1.3 ± 0.1 
  W90F4W (4,5,6,7) 11 1.3 ± 0.1 1.4 -1.7 ± 0.1 Ondansetron mCPBG Wild Type 23 0.91 ± 0.04 - -1.5 ± 0.1 
  W183F1W (5) 15 10 ± 1 11 -1.9 ± 0.2 
  W183F2W (5,7) 13 140 ± 10 160 -1.3 ± 0.1   W183F2W (4,7) 13 73 ± 6 80 -1.7 ± 0.2 
  W183F3W (5,6,7) 8 89 ± 5 99 -1.1 ± 0.1 
  W183F4W (4,5,6,7) 15 590 ± 80 650 -1.1 ± 0.1   W90F3W (5,6,7) 11 0.37 ± 0.03 1 / 2.4 -1.5 ± 0.2 
  W90F4W (4,5,6,7) 9 1.5 ± 0.1 1.6 -1.3 ± 0.1 
aAgonist used in the presence of antagonist for channel activation.  bNumber of oocytes averaged in IC50 
determination.  cThe effective concentration for half-maximal receptor inhibition.  dIC50(mutant)/IC50(wild 
type).  eThe Hill coefficient, nH, as determined from fitting the Hill equation. 
 
The effect of fluorine substitution in modulating a cation-π interaction has been well 
established.15,23-25  For both ondansetron and granisetron, incremental substitutions of 
fluorine to Trp183 increased IC50.  As in previous studies of fluorination trends, IC50 
fold-shift values were plotted against cation-π binding ability of fluorinated indoles, 
producing the “fluorination plots” shown in Figure 2.5.  Ondansetron inhibition linearly 
correlates with the energy of cation-π binding, regardless of whether 5-HT or mCPBG 
was used as an agonist. Granisetron also displayed a strong correlation with respect to 
degree of fluorination, regardless of agonist identity. 
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Figure 2.5.  Fluorination plots.  Calculated cation-π binding ability versus log[IC50/IC50(wt)] for a series of 
fluorinated tryptophan derivatives at Trp183.  Ondansetron fluorination plots for receptors activated by (a) 
mCPBG, and (b) 5-HT.  Granisetron fluorination plots for receptors activated by (c) mCPBG, and (d) 5-HT.  
Red lines are linear fits (y = mx + b) inclusive of all points.  Fit parameters (a) m: -0.15 ± 0.03, b: 5.1 ± 0.6, 
R: 0.94; (b) m: -0.18 ± 0.03, b: 6.0 ± 0.8, R: 0.96; (c) m: -0.11 ± 0.04, b: 3 ± 1, R: 0.77; (d) m: -0.14 ± 0.06, 
b: 5 ± 2, R: 0.82. 
 
We interpret these results as establishing a cation-π interaction between each drug and 
Trp183.  The results of Figure 2.5 highlight the value of having two distinct agonists to 
evaluate an antagonist.  With 5-HT as the agonist, we see linear fluorination plots for the 
antagonists.  The agonist alone, 5-HT, shows a similar plot in a study of its EC50.  We 
corrected for this by always using a 5-HT dose of 2 x EC50 for the particular fluorination 
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mutant.  Nevertheless, there could be concern about deconvoluting the effect of 
fluorination on the agonist vs. the antagonist.  With mCPBG as the agonist, there is no 
such concern, as it does not respond to fluorination at Trp183 in a manner consistent with 
a cation-π interaction.  Thus, the fluorination trends seen in Figure 2.5 can confidently be 
assigned as reflecting the response of the antagonist to the mutation.  We also note that 
the fluorination effect remains regardless of the structural identity of the cation.  
Ondansetron, with a N-akylimidazolium moiety, and granisetron, with a tertiary 
ammonium, show similar trends at the same residue, which is evidence that their binding 
orientations are similar. 
While the general trends in our data are clear, the detailed behaviors of the F2Trp 
unnatural amino acids present interesting details. In the fluorination plots, 5,7-F2Trp, a 
residue that we have used extensively, deviates from the line set by the other derivatives, 
especially for granisetron.  The effect is evident, but much less pronounced, in studies of 
ondansetron. We considered the possibility that an additional unique, perhaps steric, 
feature of 5,7-F2Trp was influencing the analysis. 
As such, we prepared 4,7-F2Trp (Scheme 2.1), which should have the same cation-π 
binding ability, but different steric requirements. Synthesis began by direct formation of 
4,7-difluoroindole (1) in a Bartoli reaction between the appropriate nitrodifluorobenzene 
and vinyl magnesium bromide.26,27  In a sequence similar to Gilchrist et. al.28 the 
difluoroindole (1) was then reacted with ethyl-3-bromo-2-hydroxyiminopropanoate to 
yield the oxime (2), which was then reduced using aluminum/mercury amalgam.  The 
amine of the resulting amino acid ester was protected with the photocleavable 2-
nitroveratryloxycarbonyl (NVOC), and the ester hydrolyzed with sodium hydroxide.  
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Conversion to the cyanomethyl ester (3) gave material suitable for acylation of the 
dinucleotide dCA, and for preparation of tRNA necessary for incorporation into the 
5-HT3R (methods described previously).29 The unnatural amino acid prepared by this 
route is, of course, racemic, but only the natural L configuration will be incorporated; the 
ribosome of the Xenopus oocyte in effect performs a kinetic resolution. 
Scheme 2.1. 
 
 
From an electrostatic point of view, 5,7-F2Trp and 4,7-F2Trp are, to first order, 
indistinguishable, and so they should be equivalent in a cation-π interaction. This is born 
out in the EC50 data for serotonin (Table 2.1), where the two F2Trp residues differ only by 
a factor of two, while the full fluorination series spans more than a factor of 150. In 
contrast, the EC50 values for mCPBG differ by 8-fold for the two F2Trps.  Recall that 
mCPBG does not make a cation-π interaction to the Trp. This again suggests that specific 
steric interactions at Trp183 may be involved. 
In the granisetron IC50 plots, 4,7-F2Trp gives a quite different response than 5,7-F2Trp.  
We have suggested the possibility of a special steric effect with 5,7-F2Trp, but 
5,6,7-F3Trp and 4,5,6,7-F4Trp both have fluorine atoms at the positions in 5,7-F2Trp, yet 
follow the trend indicative of electrostatics as the major determinant to binding.  As such, 
we cannot provide a simple rationalization of the behaviors of the two difluoro-Trp 
residues.  Nevertheless, the consistent linear trend of Trp, F1Trp, F3Trp, and F4Trp 
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(Figure 2.5) provides compelling evidence for a cation-π interaction to Trp183 for both 
granisetron and ondansetron. 
Both ondansetron and granisetron either increase their potencies or retain their 
potencies when Trp90 is mutated to F3Trp or F4Trp, respectively.  This holds for both 
5-HT and mCPBG used as the agonist, which indicates no cation-π interaction at that site.  
A loss of potency would be expected if a cation-π interaction were present.   We noted 
above that Yan and White concluded that Trp90 is important for binding of ondansetron 
and granisetron.14  Based on the observation that granisetron and ondansetron responded 
differently to a W90F mutation, the authors concluded that the bicyclic amine of 
granisetron interacts with Trp90.  Our results position this moiety in contact with Trp183, 
and we conclude that the importance of Trp90 is for reasons other than a cation-π 
interaction.   
The present results provide evidence that the cationic centers of ondansetron and 
granisetron are oriented towards Trp183, and not towards Trp90.  Establishing a cation-π 
interaction with ondansetron and granisetron at Trp183 determines a binding orientation 
for these antagonists.  Docking studies of granisetron performed in other laboratories 
have generated a series of poses, some of which are consistent with the cation pointed 
towards Trp183.  Our data provide evidence that these poses are the most viable, while 
those with the cation pointed away from Trp183 are not likely to be relevant. 
2.4 SUMMARY 
We have identified a cation-π interaction with the antagonists ondansetron and 
granisetron to Trp183 in the 5-HT3AR.  This interaction is consistent with the binding 
mode of 5-HT, but not mCPBG.  The use of agonists with alternate binding modes 
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validates our data as direct measurements of ondansetron and granisetron.  Thus, the 
common antagonists follow the basic pharmacophore established by 5-HT, and not the 
structurally dissimilar agonist mCPBG.  
2.5 METHODS 
Procedures for incorporating unnatural amino acids, expressing receptors in Xenopus 
oocytes, and characterization by electrophysiology followed established protocols.29 
2.5.1 Protein Expression in Xenopus Oocytes. The mouse 5-HT3A receptor in the 
pGEMHE vector was linearized with the restriction enzyme Sbf I (New England Biolabs).  
mRNA was prepared by in vitro transcription using the mMessage Machine T7 kit 
(Ambion).  Unnatural mutations were introduced by the standard Stratagene 
QuickChange protocol using a TAG mutation at W183 and W90.  Stage V-VI Xenopus 
laevis oocytes were injected with mRNA. Each cell was injected with 50 nL containing 
only mRNA (5 ng) for wild type 5-HT3AR or a mixture of mRNA (5-32 ng, typically ~12 
ng) and tRNA (18-30 ng, typically ~18 ng) for unnatural amino acids.  Uncharged full 
length tRNA was injected as a negative control. 
2.5.2 Electrophysiology.  Electrophysiological experiments were performed 24-48 hours 
after injection using the OpusXpress 6000A instrument (Axon Instruments) in two-
electrode voltage clamp mode at a holding potential of -60 mV.  The running buffer was 
Ca2+-free ND96 solution (96 mM NaCl, 2 mM KCl, 1 mM MgCl2 and 5 mM HEPES, pH 
7.5).  Serotonin hydrochloride (5-HT) was purchased from Alfa Aesar.  1-(3-
Chlorophenyl)biguanide (mCPBG) was purchased from Sigma-Aldrich.  Granisetron 
hydrochloride and ondansetron hydrochloride were purchased from Tocris Bioscience. 
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For EC50 determinations, oocytes were superfused with running buffer at 1 mL/min for 
30 s before application of 5-HT or mCPBG for 15 s followed by a 116 s wash with the 
running buffer.  Data were sampled at 125 Hz and filtered at 50 Hz. Dose-response data 
were obtained for ≥ 9 concentrations of 5-HT or mCPBG on ≥ 9 cells.  All EC50 and Hill 
coefficient values were obtained by fitting dose-response relations to the Hill equation 
(Inorm = 1 / [ 1 + (EC50/[agonist])n]), and are reported as means ± standard error of the fit. 
For IC50 determinations, oocyte response to either 5-HT or mCPBG at 2 x EC50 for 
each receptor was measured before application of antagonists by application of the 
agonist for 15 s, followed by 116 s of wash with the running buffer.  Granisetron or 
ondansetron doses were then pre-applied and the oocyte allowed to incubate for 60 s, 
followed by application of a mixture of the antagonist dose with 5-HT or mCPBG at 
2-fold EC50.  The oocytes were then washed with the running buffer for 116 s.  Every 
four antagonist doses, the oocytes were washed for 10 min, and oocyte response 
reconfirmed using either 5-HT or mCPBG at 2-fold EC50.  Oocytes that did not give 
consistent responses to 5-HT or mCPBG alone throughout the experiment were discarded.  
Dose-response data were obtained for ≥ 8 concentrations of granisetron or ondansetron 
on ≥ 8 cells.  All EC50 and Hill coefficient values were obtained by fitting Dose-response 
relations to the Hill equation (Inorm = 1 / [ 1 + (EC50/[antagonist])n]), and are reported as 
means ± standard error of the fit. 
For Schild analysis, the protocol for EC50 determinations was repeated with the 
following changes: during the course of the experiment (after each minimal EC50 curve 
was determined) running buffer containing granisetron or ondansetron was used for the 
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subsequent EC50 determinations.  Agonist applications in the subsequent EC50 
determinations contained the same concentration of antagonist as the running buffer. 
2.5.3 Synthesis. 4,7-Difluoroindole (1)– A solution of 3.5 mL (32.3 mmol) of 1,4-
difluoro-2-nitrobenzene in 30 mL of dry THF was cooled in an acetone/dry ice bath 
to -78 °C under argon.  A 1 M solution of vinylmagnesium bromide in THF (100 mL, 
100 mmol, 3 eq.) was added via cannula over 20 min.  The reaction was stirred for 1 h 
at -78 °C.  Reaction quenched by the addition of 20 mL of saturated aq. NH4Cl.  Upon 
warming to room temperature, 20 mL of water was added, which formed a thick 
emulsion.  The reaction was filtered through a layer of sand and washed copiously with 
ethyl acetate.  The organic layer was separated and dried over Na2SO4.  The solvent was 
removed under reduced pressure to yield a brown oil containing multiple compounds.  
Purification by silica gel chromatography using a gradient of 3% to 10% ethyl acetate in 
hexanes yielded a slightly volatile amber oil. 871 mg (18%). Silica TLC (4% EtOAc in 
hexanes) Rf = 0.26, stains red/pink using p-anisaldehyde.  1H NMR (300 MHz, CDCl3): δ 
8.47 (br, 1H), 7.18 (t, J = 2.8 Hz, 1H), 6.78 (ddd, J = 10.3, 8.6, 3.5 Hz, 1H), 6.71 – 6.60 
(m, 2H). 19F NMR (282 MHz, CDCl3):  δ -124.1 – -129.8 (m), -139.4 – -142.3 (m).  13C 
NMR (126 MHz, CDCl3): δ 152.2 (dd, J = 239, 2.4 Hz), 145.8 (dd, J = 238.6, 3.0 Hz), 
126.0 (dd, J = 15.9, 11.5 Hz), 124.7, 119.9 (dd, J = 24.9, 5.7 Hz), 106.4 (dd, J = 18.9, 8.2 
Hz), 103.9 (dd, J = 18.9 8.2 Hz), 99.8. HRMS EI(+) m/z for C8H5NF2 found 153.0395, 
calculated 153.0390 (M+•). 
Ethyl 3-(4,7-difluoro-1H-indol-3-yl)-2-(hydroxyimino)propanoate (2)– A solution of 
424 mg (2.8 mmol, 2 eq.) of 4,7-difluoroindole in 10 mL CH2Cl2 was added to 290 mg 
(1.4 mmol, 1 eq.) of ethyl 3-bromo-2-(hydroxyimino)propanoate and 205 mg (1.9 mmol, 
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1.4 eq.) of Na2CO3.  The mixture was stirred overnight under argon at room temperature.  
The reaction was diluted with 50 mL of CH2Cl2 and 50 mL of ethyl acetate, and washed 
with 50 mL of water, then 50 mL of brine.  The organic phase was separated and dried 
over Na2SO4.  Purification was performed by silica chromatography, gradient of 25% to 
40% EtOAc in hexanes, to yield a white solid. 195 mg (50%). 1H NMR (300 MHz, 
CD3CN): δ 9.93 (s, 1H), 9.64 (br, 1H), 7.01 (m, 1H), 6.81 (ddd, J = 10.5, 8.5, 3.5 Hz, 1H), 
6.67 (ddd, J = 10.7, 8.5, 3.2 Hz, 1H), 4.21 (q, J = 7.2 Hz, 2H), 4.12 (d, J = 1.1 Hz, 2H), 
1.23 (t, J = 7.1 Hz, 3H).  19F NMR (282 MHz, CD3CN):  δ -130.99 – -131.20 (m), -
141.02 – -141.19 (m).  13C NMR (126 MHz, CDCl3): δ 164.80, 153.77 (dd, J = 240.4, 2.3 
Hz), 152.58, 146.84 (dd, J = 238.1, 2.9 Hz), 127.18 (dd, J = 16.4, 12.1 Hz), 125.12, 
119.55 (dd, J = 22.1, 5.7 Hz), 110.05 (dd, J = 3.7, 1.6 Hz), 106.94 (dd, J = 19.7, 9.1 Hz), 
104.42 (dd, J = 22.9, 7.5 Hz), 62.28, 21.96 (d, J = 3.1 Hz), 14.33.  HRMS FAB(+) m/z for 
C13H13O3N2F2 found 283.0888, calculated 283.0894 (M+H). 
N-(2-nitroveratryloxycarbonyl)-4,7-difluorotryptophan cyanomethyl ester (3)– In a 
beaker 1.5 g of 8-20 mesh aluminum was stirred under 15 mL of 2 M NaOH for 5 min.  
After decanting, the aluminum was rinsed with water and 15 mL of a 2% HgCl2 solution 
was added and stirred slowly.  The solution was decanted after formation of the Hg-Al 
(~10 minutes) and added to 195 mg (0.69 mmol) of 2 in 20 mL of 9:1 dioxane:water.  
The reaction was stirred slowly at room temperature overnight (~24 h).  The reaction was 
filtered through fluted paper, then applied to a silica plug, eluting with EtOAc followed 
by 4% MeOH in EtOAc.  After concentration under reduced pressure, the resulting oil 
was used directly.  The oil was dissolved in 20 mL of 1:1 THF:water and 151 mg of 
Na2CO3 (1.42 mmol), and 248 mg of 4,5-dimethoxy-2-nitrobenzyl chloroformate (0.9 
  
29 
mmol) was added.  The reaction was stirred at room temperature for 3 h, followed by 
dilution with 20 mL CH2Cl2 and 20 mL 1 N HCl.  The organic phase was separated, 
washed with brine, and dried over Na2SO4.  Initial purification by silica chromatography 
20% to 40% EtOAc in hexanes did not separate the product from nitroveratryl side 
products.  This mixture was dissolved in 3 mL dioxane and 3 mL 2N NaOH and stirred 
for 15 min.  The reaction was quenched with 6 mL 1 N HCl and diluted with 20 mL 
EtOAc.  The organic phase was separated, and the aqueous phase washed with 20 mL 
CH2Cl2.  The combined organic phases were dried over Na2SO4, concentrated under 
reduced pressure, and filtered through a silica plug, eluting with EtOAc followed by 
0.5 % acetic acid in EtOAc.  This residue (~35 mg, 0.07 mmol) was dissolved in 1 mL 
DMSO, and added to a reaction flask containing 0.5 mL of chloroacetonitrile (7.9 mmol) 
and 0.5 mL of triethylamine (3.6 mmol).  The reaction was allowed to stir at room 
temperature for 5 h.  The reaction was poured onto a dry column of silica and eluted with 
EtOAc to recover 23 mg of a yellow solid (6%, 4 steps).  1H NMR (300 MHz, DMSO-
d6): δ 11.71 (s, 1H), 8.21 (d, J = 7.7 Hz, 1H), 7.68 (s, 1H), 7.23 (d, J = 2.0 Hz, 1H), 7.09 
(s, 1H), 6.92 – 6.80 (m, 1H), 6.74 – 6.62 (m, 1H), 5.39 – 5.21 (m, 2H), 4.99 (s, 2H), 4.48 
– 4.35 (m, 1H), 3.85 (s, 3H), 3.83 (s, 3H), 3.32 – 2.99 (m, 2H).  19F NMR (282 MHz, 
DMSO-d6): δ -130.18 (dd, J = 22.4, 9.9 Hz), -138.53 (ddd, J = 22.6, 10.6, 3.1 Hz).  13C 
NMR (126 MHz, DMSO-d6): δ 171.56, 156.03, 153.83, 152.62 (d, J = 239.6 Hz), 148.15, 
146.10 (dd, J = 238.5, 2.2 Hz), 139.55, 128.09, 126.70 (dd, J = 16.1, 12.2 Hz), 126.36, 
118.82 – 118.30 (m), 116.08, 110.61, 109.18, 108.59, 106.23 (dd, J = 18.8, 8.7 Hz), 
103.90 – 103.23 (m), 63.15, 56.55, 55.30, 49.97, 27.84.  HRMS FAB(+) m/z for 
C23H20O8N4F2 found 518.1271, calculated 518.1249 (M+•). 
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Chapter 3 
Continuing Studies of 5-HT3A 
 
 
3.1 ABSTRACT 
The serotonin type 3 receptor (5-HT3R) is a ligand-gated ion channel that mediates fast 
synaptic transmission in the central and peripheral nervous systems.  The 5-HT3R is a 
therapeutic target, and the clinically available drugs ondansetron and granisetron inhibit 
receptor activity.  Their inhibitory action is through competitive binding to the native 
ligand binding site, and Chapter 2 established a binding orientation.  In this chapter, 
mouse 5-HT3A receptors are heterologously expressed in Xenopus oocytes using 
unnatural amino acid mutagenesis to probe for other interactions in the ligand binding 
pocket.  No substantive interactions for inhibition were found for granisetron and 
ondansetron.  During the course of these studies, an interesting interaction between the 
partial agonist meta-chlorophenylbiguanide and 5-HT3A was discovered. 
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3.2 INTRODUCTION 
The work in Chapter 2 established a cation-π interaction for the antiemetic drugs 
granisetron and ondansetron (Figure 3.1) with tryptophan 183 (W183, TrpB) of the 
serotonin type 3A (5-HT3A) receptor.  Although this work established a binding 
orientation of granisetron and ondansetron, it only established one direct interaction to 
the 5-HT3AR.  The soluble acetylcholine binding protein (AChBP) found in the snail 
cholinergic synapse is homologous to the extracellular ligand-binding domain of 
5-HT3A.1  A high resolution x-ray structure of AChBP from Aplysia californica in 
complex with the ligand tropisetron (Figure 3.2) shows a cation-π interaction at both 
TrpB and Tyrosine C2 (TyrC2, Y234 in 5-HT3A).2  A more recent structure of AChBP 
with granisetron also shows a cation-π with TrpB and TyrC2.3  With the binding 
orientation of ondansetron and granisetron established, we sought to determine additional 
interaction(s) to 5-HT3A, including a possible cation-π interaction at TyrC2. 
 
 
Figure 3.1.  Chemical structures of drugs used in this study. (a) 5-HT3AR antagonists. (b) 5-HT3AR 
agonists. 
 
In probing a cation-π interaction at a tyrosine residue, one must consider that direct 
fluorination results in decreasing pKa of the side chain hydroxyl group; the pKa of 
tyrosine is 10.0 while the pKa of tetrafluorotyrosine is 5.3.4  While it is possible for 
receptor function to be unaffected by this shift in pKa (e.g. Nowak et al. 5), determining 
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functional changes resulting from a cation-π interaction versus hydroxyl ionization is not 
straightforward.  To circumvent this complication, one strategy is to mutate the tyrosine 
to a phenylalanine, which is then successively fluorinated.  Although this strategy 
simplifies cation-π analysis, there may be functional consequences resulting from 
removal of a hydrogen bond acceptor/donor. 
 
Figure 3.2.  Crystal structure of tropisetron binding to Aplysia californica AChBP (PDB 2WNC).  Detail of 
tropisetron cation-π interactions with TyrC2 and TrpB (Y234 and W183 in 5-HT3A numbering) and TrpB 
backbone carbonyl shown. 
 
In 5-HT3A, TyrC2 has been previously studied with the agonist serotonin (5-HT, 
Figure 3.1).6  The concentration of agonist required to achieve 50% of the maximum 
signal (EC50) could not be measured for the full complement of fluorinated phenylalanine 
mutations; only the EC50 4-F-Phe could be determined.  Measurement of a possible 
TrpB%
W183%
TyrC2%
Y234%
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cation-π for ondansetron and granisetron with only two data points (Phe and 4-FPhe) 
would not be very compelling, and so a twofold strategy was employed.  First, the partial 
agonist meta-chlorophenylbiguanide (mCPBG, Figure 3.1) has been shown to make 
different interactions with 5-HT3A than 5-HT,7 and so EC50 measurements of fluorinated 
phenylalanines using mCPBG were attempted.  Second, other mutations beyond 
fluorinated phenylalanines were made to probe for a cation-π interaction (Figure 3.3).  
These efforts resulted in interesting insights into the binding of mCPBG directly, which 
were explored independently from antagonist binding. 
 
 
Figure 3.3.  Chemical structures of the natural and unnatural amino acids used in this study. 
 
In addition to the putative cation-π interaction at TyrC2, both 5-HT3A antagonist-
containing AChBP crystal structures show a hydrogen bond between the ligand and the 
backbone carbonyl of TrpB.2,3  The functional importance of this interaction was also 
examined.  The strategy employed for this measurement was conversion of the backbone 
amide to a backbone ester.  This amide to ester mutation was made by nonsense 
suppression of the N+1 residue using an α-hydroxy acid in place of an α-amino acid.8 
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As in Chapter 2, the functional data collected for the antagonists is the concentration 
required to inhibit 50% of the signal (IC50) generated from application of 2-fold the EC50 
of an agonist.  When possible, an IC50 is separately measured for a particular mutant 
receptor using 5-HT and mCPBG to control for possible effects of the agonist behavior.9 
3.3 RESULTS AND DISCUSSION 
3.3.1 Interactions of Ondansetron and Granisetron with 5-HT3A.  At TyrC2, 
mutation to 3,5-F2Phe and 3,4,5-F3Phe results in no detectable signal from 5-HT as the 
agonist.  Fortunately, fluorine is not the only electron-withdrawing group at our disposal.  
Installation of a cyano group onto a benzene ring reduces the calculated cation-π binding 
ability of the ring to a gas phase sodium ion (Na+) to 15.7 kcal/mol from 27.1 kcal/mol, 
which is less deactivating towards binding than F3-benzene (12.4 kcal/mol), but more 
deactivating than F2-benzene (16.8 kcal/mol).10  A cyano group, however, is larger than a 
fluorine, so steric effects may be observed in a receptor experiment.  The sterically 
similar bromo group, which is less deactivating (21.6 kcal/mol) than cyano, can be used 
to test for a possible steric perturbation. 
When 5-HT is the agonist, the IC50 for granisetron at TyrC2 with 4-BrPhe is 
essentially wild type, with only a 1.4-fold loss of inhibition (Table 3.1).  For ondansetron, 
the IC50 for 4-BrPhe is also wild type  In order to take into account possible steric effects, 
4-BrPhe rather than the wild type receptor is used as the reference point when examining 
the change in cation-π binding ability.  Mutation of TyrC2 to 4-CN-Phe slightly reduces 
the inhibition of granisetron and ondansetron by 2.2-fold and 1.8-fold, respectively, from 
4-BrPhe (Table 3.2).  From these data alone, we would not consider electrostatics at 
TyrC2 to play a significant role in the function of granisetron and ondansetron.  For 
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example, acetylcholine makes a cation-π interaction with TrpB (W149) of the muscle 
nicotinic acetylcholine receptor (nAChR), and the loss of function in going from 5-BrTrp 
to 5-CNTrp is 57-fold.11 
Table 3.1.  IC50 data for wild type and mutant 5-HT3AR for granisetron and ondansetron in response to 
5-HT or mCPBG. 
 
 
 
aNumber of oocytes averaged in IC50 determination.  bThe effective concentration for half-maximal 
receptor inhibition.  cIC50(mutant)/IC50(wild type).  dThe Hill coefficient, nH, as determined from fitting the 
Hill equation. 
 
The inhibition of granisetron and ondansetron at TyrC2 was then examined using 
mCPBG as the agonist (Table 3.1).  Both antagonists were better at inhibiting the 4-
BrPhe mutant receptor than the wild type receptor by 6.3-fold for granisetron and 4.1-
fold for ondansetron.  Converting 4-BrPhe into 4-CNPhe reduced the ability of 
granisetron and ondansetron to inhibit the receptor by 11-fold and 8.1-fold, respectively 
(Table 3.2).  Considering these data independently from the IC50 data using 5-HT, there is 
a slight electrostatic dependence of the inhibitory ability of the antagonists to TyrC2.  
This electrostatic dependence is not as strong as one would expect if TyrC2 were the 
primary determinant of binding, and can be contrasted to the strong electrostatic 
dependence of inhibition measured for TrpB in Chapter 2. 
Antagonist Agonist Na Fold Shiftc
Wild Type 27 0.78 ± 0.04 - -1.40 ± 0.08
Y234 4-BrPhe 13 1.06 ± 0.06 1.4 -1.5 ± 0.1
Y234 4-CNPhe 13 2.3 ± 0.2 2.9 -1.5 ± 0.1
L184 Lah 12 2.52 ± 0.08 3.2 -2.0 ± 0.1
Wild Type 27 1.51 ± 0.07 - -1.49 ± 0.09
Y234 4-BrPhe 14 0.24 ± 0.04 1 / 6.3 -1.1 ± 0.2
Y234 4-CNPhe 5 2.6 ± 0.1 1.7 -1.40 ± 0.08
Wild Type 21 0.87 ± 0.04 - -1.56 ± 0.09
Y234 4-BrPhe 10 0.90 ± 0.06 1.0 -1.18 ± 0.08
Y234 4-CNPhe 14 1.58 ± 0.08 1.8 -1.47 ± 0.08
L184 Lah 8 3.8 ± 0.2 4.4 -1.8 ± 0.2
Wild Type 23 0.91 ± 0.04 - -1.47 ± 0.08
Y234 4-BrPhe 12 0.22 ± 0.04 1 / 4.1 -1.1 ± 0.2
Y234 4-CNPhe 7 1.78 ± 0.08 2.0 -1.30 ± 0.06
Mutation IC50 (nM)b Hilld
Granisetron
Ondansetron
mCPBG
5HT
5HT
mCPBG
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Table 3.2.  Fold shift of antagonist IC50 referenced to 4-BrPhe. 
 
 
 
aIC50 data from Table 3.1. b IC50(mutant)/IC50(reference). cReference IC50 value used in place of wild type. 
   
Examining the TyrC2 results of granisetron and ondansetron when using the agonists 
5-HT and mCPBG independently, one might come to different conclusions—namely, a 
lack of electrostatic dependence versus a weak electrostatic dependence.  This reiterates 
the discussion in Chapter 2 regarding the importance of having two distinct agonists to 
evaluate an antagonist.  In examining the electrostatic dependence of inhibition at TrpB, 
the analysis benefited from the trend of many mutations.  In the case of TyrC2, we are 
limited to comparing a single mutation pair.  To better understand the discrepancy of the 
5-HT and mCPBG results, it is worth discussing the magnitude of the discrepancy.  The 
fold-shift discrepancy (FSD) will be defined as the ratio of the mutation pair fold-shift for 
one agonist to the mutation pair fold-shift to the second agonist, e.g.  
FSD =
IC50 (mutant, agonist 1) IC50 (reference, agonist 1)
IC50 (mutant, agonist 2) IC50 (reference, agonist 2)
 
  Starting with granisetron, the TyrC2 IC50 fold shift of 4-CNPhe/4-BrPhe goes from 
2.2-fold using 5-HT to 11-fold using mCPBG, resulting in a FSD of 5-fold comparing 
mCPBG over 5-HT.  For ondansetron, the IC50 for 4-CNPhe/4-BrPhe is 1.8-fold using 
5-HT to 8.1-fold using mCPBG, giving a FSD of 4.5-fold.  These FSD values are close to 
Antagonist Agonist
Y234 4-BrPhec
Y234 4-CNPhe
Y234 4-BrPhec
Y234 4-CNPhe
Y234 4-BrPhec
Y234 4-CNPhe
Y234 4-BrPhec
Y234 4-CNPhe
Mutation
Granisetron
Ondansetron
5HT
mCPBG
5HT
mCPBG
Fold Shiftb
1.06 ± 0.06 -
2.3 ± 0.2 2.2
0.24 ± 0.04 -
2.6 ± 0.1 11
0.90 ± 0.06 -
1.58 ± 0.08 1.8
0.22 ± 0.04 -
1.78 ± 0.08 8.1
IC50 (nM)a
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the FSD values measured in Chapter 2.  For example, for granisetron at TrpD (W90), the 
FSD for 4,5,6,7-F4Trp/Trp is 3.3 comparing mCPBG over 5-HT.  For the IC50 values 
measured thus far, this variability in the data is common.  These data indicate that 
interpretations of small shifts in IC50 should be made with caution; even an 11-fold 
4-CNPhe/4-BrPhe ratio for TyrC2 may be insufficient to claim an electrostatic effect. 
The backbone carbonyl of TrpB (W183) was then examined by mutation of L184 to 
the corresponding α-hydroxy acid of leucine (Lah, Table 3.1).  The mutation L184Lah is 
known to completely abolish agonist activity for mCPBG,7 so the IC50 values for 
granisetron and ondansetron could only be made using 5-HT as the agonist.  The 
L184Lah fold-shifts for granisetron and ondansetron are 3.2-fold and 4.4-fold, 
respectively.  These shifts are fairly small compared to previous measurements, e.g. in 
the nAChR subtype (α4)3(β2)2 the fold-shift for the drug cytisine is 27-fold.12  This 
relatively small fold-shift shows a hydrogen bond to the backbone carbonyl of TrpB is 
not a strong functional determinant for inhibition of 5-HT3A. 
3.3.2 Examination of agonists 5-HT and mCPBG at TyrC2.  Considering the results of 
our studies of granisetron and ondansetron with TyrC2, fluorinated phenylalanine 
mutations were reexamined using 5-HT.  As shown in Table 3.3, removal of the 4-
hydroxy substituent by mutation of Tyr to Phe resulted in a 7-fold loss of function.  The 
loss of function in replacement of the 4-hydroxy with a 4-methyl was too small to be 
considered significant, indicating that the hydrogen-bonding features of an alcohol are 
not important for channel function with 5-HT.  This point is recapitulated by the wild 
type behavior of 4-BrPhe.  As seen in previous studies,6 mutation to 4-FPhe gave a 
measureable EC50, but 3,5-F2Phe did not respond to 5-HT.  It was reasoned that the lack 
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of a 4-position substituent, along with the change in ring electronic structure, was the 
cause of non-responsive receptors.6 
Table 3.3.  EC50 data for wild type and mutant 5-HT3AR in response to 5-HT or mCPBG. 
 
 
aNumber of oocytes averaged in EC50 determination.  bThe effective concentration for half-maximal 
receptor activation.  cEC50(mutant)/EC50(wild type).  dThe Hill coefficient, nH, as determined from fitting 
the Hill equation.  eNo measurable response 
 
TyrC2 was then examined using mCPBG as the agonist (Table 3.3).  Like 5-HT, 
removal of the 4-hydroxy by mutation to Phe resulted in a loss in channel function, 
although to a larger extent (18-fold).  Replacement of the 4-hydroxy substituent with a 
4-methyl gives nearly wild type behavior for mCPBG, which indicates the need of a 
4-position substituent.  As with 5-HT, mutation to 3,5-F2Phe (which lacks a 4-position 
substituent) gave no response to mCPBG.  Interestingly, 3,4,5-F3Phe gave a measureable 
Agonist Na Fold Shiftc
Wild Type 25 1.57 ± 0.05 - 2.1 ± 0.16
Y234 Phe 11 10.9 ± 0.6 6.9 2.0 ± 0.2
Y234 4-MePhe 16 2.7 ± 0.1 1.7 1.9 ± 0.1
Y234 4-F1Phe 10 6.3 ± 0.2 4.0 2.1 ± 0.1
Y234 3,5-F2Phe 16 - -
Y234 3,4,5-F3Phe 8 - -
Y234 4-BrPhe 14 1.48 ± 0.04 1 / 1.1 1.9 ± 0.1
Y234 4-CNPhe 15 20.8 ± 0.8 13 2.4 ± 0.2
Y234 OMeTyr 8 2.6 ± 0.1 1.7 1.8 ± 0.1
Y234 3-F-OMeTyr 6 10.7 ± 0.6 6.8 1.9 ± 0.2
Y234 3,5-F2-OMeTyr 28 - -
Y234 2,3,5,6-F4-OMeTyr 8 - -
L184 Lah 15 14.7 ± 0.4 9.4 2.11 ± 0.09
Wild Type 9 0.50 ± 0.02 - 2.2 ± 0.1
Y234 Phe 13 8.8 ± 0.4 18 1.62 ± 0.09
Y234 4-MePhe 13 0.87 ± 0.04 1.7 1.40 ± 0.07
Y234 4-F1Phe 15 1.6 ± 0.1 3.2 2.1 ± 0.3
Y234 3,5-F2Phe 16 - -
Y234 3,4,5-F3Phe 7 16 ± 1 32 2.0 ± 0.2
Y234 4-BrPhe 9 0.049 ± 0.002 1 / 10 3.5 ± 0.7
Y234 4-CNPhe 14 0.63 ± 0.02 1.3 1.9 ± 0.1
Y234 OMeTyr 19 0.06 ± 0.002 1 / 8.3 4.1 ± 0.5
Y234 3-F-OMeTyr 7 0.10 ± 0.01 1 / 5 3.0 ± 0.5
Y234 3,5-F2-OMeTyr 10 4.8 ± 0.3 9.6 2.1 ± 0.3
Y234 2,3,5,6-F4-OMeTyr 8 - -NRe
5HT
mCPBG
Mutation EC50 (µM)b Hilld
NRe
NRe
NRe
NRe
NRe
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EC50 of 16 µM, while remaining unresponsive to 5-HT.  It has been previously shown 
that mCPBG does not make a cation-π interaction at TrpB.7  Such an interaction may 
exist at TyrC2, but determination with competing steric effects adds an additional 
challenge. 
Mutation of TyrC2 to 4-BrPhe results in a 10-fold gain of function for mCPBG.  Wild 
type function is measured for 4-CNPhe, but when referenced to 4-BrPhe the 4-CN 
substituent causes a 13-fold increase in EC50.  In addition to the importance of sterics of 
the 4-position, the polarity of the substituent also plays a role.  These data provided the 
motivation to attempt a series of unnatural amino acids that were previously untested in 
the Dougherty group—namely successive fluorination of tyrosine residues in which the 
4-hydroxyl has been methylated. 
The amino acids 3-F-OMeTyr and 3,5-F2-OMeTyr were purchased and used without 
purification.  The amino group was protected by 6-nitroveratryl chloroformate, followed 
by formation of the cyanomethyl ester (Scheme 3.1).  Coupling to deoxycytidine-
adenosine (dCA) and then ligation by enzymatic T4 ligase as previously described13 gave 
suitable tRNA for unnatural amino acid mutagenesis.  The amino acid 2,3,5,6-F4-
OMeTyr was kindly provided by Matthew Rienzo. 
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Scheme 3.1. 
 
Evidence for a cation-π interaction in a receptor is often obtained by a ‘fluorination 
plot’ in which the ab initio quantum mechanical binding energy of Na+ to the π face of 
the ring system is plotted against the log of the functional change in EC50.11  In 
preparation for construction of such a plot, the Na+ binding energies of the fluorinated 
tyrosines  were calculated at the 6-311G** level using Spartan 08.14  Electrostatic 
potential surfaces were calculated and contoured to -25 to +25 kcal/mol (Figure 3.4).15  
The cation-π binding energies of the O-methylated Tyr amino acids start at 27.3 kcal/mol 
for OMeTyr, and remain weakly attractive to Na+ in the fully fluorinated 2,3,5,6-F4-
OMeTyr at 12.6 kcal/mol (similar to 3,4,5-F3Phe at 12.4 kcal/mol). 
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Figure 3.4.  Ab initio 6-311G** electrostatic potential surfaces of side chains corresponding to unnatural 
amino acids.  Calculated binding energies of a gas phase Na+ are shown for each ring system.  Red 
signifies a value greater than or equal to the maximum in negative potential (-25 kcal/mol), and blue 
signifies a value greater than or equal to the maximum in positive potential (+25 kcal/mol). 
 
Mutation of TyrC2 to OMeTyr results in a 8.3-fold gain of function for mCPBG, 
which reinforces the notion that both polarity and size is important at the 4-position.  
Using OMeTyr as the reference point, a single fluorine (3-F-OMeTyr) results in a small 
1.7-fold loss of function, and two fluorines (3,5-F2-OMeTyr) results in a large 63-fold 
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loss of function.  In addition to the loss of function (EC50), the expression levels of 
3,5-F2-OMeTyr at TyrC2 are very low; extended oocyte incubation times (48 hours vs. 
24 hours) and doubling mRNA/tRNA injections gives receptors that average ~100 nA of 
response (vs. multiple µA for other unnatural amino acid mutations).  This low level of 
measureable signal precludes the use of 3,5-F2-OMeTyr for determination of antagonist 
binding.  No signal was detected for mCPBG or 5-HT when 2,3,5,6-F4-OMeTyr was 
installed at TyrC2. 
The steric and polar requirements for substituents at the 4-position of TyrC2 
complicate the analysis of a possible cation-π interaction.  Two fluorination plots were 
constructed using different reference amino acids, but each mutation contains a 
substituent in the 4-position.  The first plot (Figure 3.5a) was constructed referencing 4-
MePhe, and contains the hydrophobic residues 4-FPhe and 3,4,5-F3Phe (Table 3.4).  The 
second plot (Figure 3.5b) was constructed using OMeTyr as the reference, and contains 
the mutations with polar groups in the 4-position (3-F-OMeTyr; 3,5,-F2-OMeTyr; 4-
CNPhe; 4-BrPhe; Table 3.4). 
Table 3.4. Fold Shift of EC50 data referenced to 4-MePhe or OMeTyr. 
 
 
 
aEC50 data from Table 3.3. b EC50(mutant)/EC50(reference). cReference EC50 value used in place of wild 
type for hydrophobic substituents in the 4-position.  dReference EC50 value used in place of wild type for 
polar substituents in the 4-position. 
 
Agonist Fold Shiftb
Y234 4-Me-Phec 0.87 ± 0.04 -
Y234 4-F1-Phe 1.6 ± 0.1 1.8
Y234 3,4,5-F3-Phe 16 ± 1 18
Y234 OMeTyrd 0.06 ± 0.002 -
Y234 3-F-OMeTyr 0.10 ± 0.01 1.7
Y234 3,5-F2-OMeTyr 4.8 ± 0.3 80
Y234 4-Br-Phe 0.049 ± 0.002 0.82
Y234 4-CN-Phe 0.63 ± 0.02 11
mCPBG
mCPBG
Mutation EC50 (µM)a
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The “hydrophobic” fluorination plot in Figure 3.5a is indicative of a cation-π 
interaction for mCPBG at TyrC2, albeit with a small number of measurements.  The 
“polar” fluorination plot in Figure 3.5b follows a similar trend with 3-F-OMeTyr and 
4-CNPhe, but both 4-BrPhe and 3,5-F2-OMeTyr are considerably outside the trend.  The 
slope of the fit for a fluorination plot has been interpreted to correlate with the strength of 
a cation-π interaction.16  The equivalent slopes of both fluorination plots suggests the 
measurement of the same interaction: the biguanide cation of mCPBG with TyrC2.  The 
same slope in both fluorination plots also justifies the construction of the third 
fluorination plot in Figure 3.5c.  In this plot, the same reference amino acids for polar and 
hydrophobic groups in the 4-position are used; however, the fit includes all points from 
both fluorination plots in Figure 3.5a and Figure 3.5b.  This combined fluorination plot 
gives evidence that a cation-π interaction plays a functional role for mCPBG with TyrC2, 
and the scatter in measurements are from imperfect control of substituent effects in the 
4-position. 
The cation-π interaction for mCPBG at TyrC2 is atypical; for cation selective Cys-
loop channels agonists tend to make a cation-π with a Trp rather than a Tyr.17  The native 
agonist 5-HT follows this trend by making a cation-π with TrpB.  This again shows that 
mCPBG and 5-HT uniquely respond to structural changes within the 5-HT3A binding 
site. 
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Figure 3.5.  “Fluorination plots” of 5-HT3AR mutagenesis.  The horizontal axis is the calculated cation-π 
binding energy (kcal/mol) values from Figure 3.4.  The vertical axis is the log of fold shift values from 
Table 3.4.  Linear fits of the data shown; inset is the fit parameters. (a) Fit of hydrophobic 4-position 
residues referenced to 4-MePhe. (b) Fit of polar 4-position residues referenced to OMeTyr. (c) Fit 
containing all points from (a) and (b) while maintaining respective reference residues. 
 
3.4  SUMMARY 
Slight changes in inhibition were found when probing TyrC2 and the backbone 
carbonyl of TrpB for the antagonists granisetron and ondansetron.  These small changes 
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in IC50 indicate these sites are not primary determinants of inhibition for 5-HT3A.  In 
probing for antagonist interactions, an interesting binding mode for the partial agonist 
mCPBG was discovered: a cation-π interaction between mCPBG and TyrC2, which is 
distinct from the native agonist 5-HT.  This interaction illustrates the differing 
requirements of 5-HT and mCPBG for activation of 5-HT3A. 
3.5 METHODS 
Procedures for incorporating unnatural amino acids, expressing receptors in Xenopus 
oocytes, and characterization by electrophysiology followed established protocols.13 
3.5.1 Protein Expression in Xenopus Oocytes. The mouse 5-HT3A receptor in the 
pGEMHE vector was linearized with the restriction enzyme Sbf I (New England 
Biolabs).  mRNA was prepared by in vitro transcription using the mMessage Machine T7 
kit (Ambion).  Unnatural mutations were introduced by the standard Stratagene 
QuickChange protocol using a TAG mutation at W183 and W90.  Stage V-VI Xenopus 
laevis oocytes were injected with mRNA. Each cell was injected with 50 nL containing 
only mRNA (5 ng) for wild type 5-HT3AR or a mixture of mRNA (5-32 ng, typically ~12 
ng) and tRNA (18-30 ng, typically ~18 ng) for unnatural amino acids.  Uncharged full 
length tRNA was injected as a negative control. 
3.5.2 Electrophysiology.  Electrophysiological experiments were performed 24-48 hours 
after injection using the OpusXpress 6000A instrument (Axon Instruments) in two-
electrode voltage clamp mode at a holding potential of -60 mV.  The running buffer was 
Ca2+-free ND96 solution (96 mM NaCl, 2 mM KCl, 1 mM MgCl2 and 5 mM HEPES, pH 
7.5).  Serotonin hydrochloride (5-HT) was purchased from Alfa Aesar.  1-(3-
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Chlorophenyl)biguanide (mCPBG) was purchased from Sigma-Aldrich.  Granisetron 
hydrochloride and ondansetron hydrochloride were purchased from Tocris Bioscience. 
For EC50 determinations, oocytes were superfused with running buffer at 1 mL/min for 
30 s before application of 5-HT or mCPBG for 15 s followed by a 116 s wash with the 
running buffer.  Data were sampled at 125 Hz and filtered at 50 Hz. Dose-response data 
were obtained for ≥ 9 concentrations of 5-HT or mCPBG on ≥ 6 cells.  All EC50 and Hill 
coefficient values were obtained by fitting dose-response relations to the Hill equation 
(Inorm = 1 / [ 1 + (EC50/[agonist])n]), and are reported as means ± standard error of the fit. 
For IC50 determinations, oocyte response to either 5-HT or mCPBG at 2 x EC50 for 
each receptor was measured before application of antagonists by application of the 
agonist for 15 s, followed by 116 s of wash with the running buffer.  Granisetron or 
ondansetron doses were then pre-applied and the oocyte allowed to incubate for 60 s, 
followed by application of a mixture of the antagonist dose with 5-HT or mCPBG at 
2-fold EC50.  The oocytes were then washed with the running buffer for 116 s.  Every 4 
antagonist doses, the oocytes were washed for 10 min, and oocyte response reconfirmed 
using either 5-HT or mCPBG at 2-fold EC50.  Oocytes that did not give consistent 
responses to 5-HT or mCPBG alone throughout the experiment were discarded.  Dose-
response data were obtained for ≥ 8 concentrations of granisetron or ondansetron on ≥ 5 
cells.  All EC50 and Hill coefficient values were obtained by fitting Dose-response 
relations to the Hill equation (Inorm = 1 / [ 1 + (EC50/[antagonist])n]), and are reported as 
means ± standard error of the fit. 
3.5.3 Synthesis.  NVOC-3-F-4-OMe-DL-phenylalanine (2a).  In a round bottom flask, 3-
F-4-OMe-DL-phenylalanine (100.7 mg, 0.472 mmol) was dissolved in 20 mL of 1:1 
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THF:water, and 101.8 mg of Na2CO3 (0.960 mmol), and 171.3 mg of 4,5-dimethoxy-2-
nitrobenzyl chloroformate (0.621 mmol) were added.  The reaction was stirred at room 
temperature for 4.5 h.  The reaction was concentrated to ~10 mL under reduced pressure, 
followed by dilution with 10 mL H2O.  The reaction was extracted 2 x 10 mL of CH2Cl2 
and the organic phases discarded.  The aqueous phase was acidified to ~pH 2 with 1 N 
HCl and extracted 2 x 10 mL of CH2Cl2.  The organic phase was separated, washed with 
brine, and dried over Na2SO4.  During slow concentration under reduced pressure, 
crystallization was induced to recover 66 mg (31%) of the desired product.  Additional 
material present in mother liquor could be recovered if desired.  1H NMR (300 MHz, 
CDCl3): δ 7.67 (s, 1H), 7.00 – 6.81 (m, 5H), 5.49 (s, 2H), 4.64 (dt, J = 8.3, 5.9 Hz, 1H), 
3.92 (s, 3H), 3.90 (s, 3H), 3.84 (s, 3H), 3.15 (dd, J = 14.3, 5.4 Hz, 1H), 3.02 (dd, J = 14.3, 
6.6 Hz, 1H).  19F NMR (282 MHz, CDCl3) δ -134.72 (m).  ESI-MS(+) m/z for 
C20H21FN2NaO9 found 471.1, calculated 475.1 (M+Na+). 
NVOC-3,5-F2-4-OMe-DL-phenylalanine (2b).  In a round bottom flask, 3,5-F2-4-OMe-
DL-phenylalanine (102.7 mg, 0.444 mmol) was dissolved in 20 mL of 1:1 THF:water, 
and 94.5 mg of Na2CO3 (0.892 mmol), and 159.7 mg of 4,5-dimethoxy-2-nitrobenzyl 
chloroformate (0.579 mmol) were added.  The reaction was stirred at room temperature 
for 15.5 h.  The reaction was concentrated under reduced pressure, followed by dilution 
with 15 mL H2O.  The reaction was extracted 3 x 10 mL of CH2Cl2 and the organic 
phases discarded.  The aqueous phase was acidified to ~pH 2 with 1 N HCl and extracted 
1 x 10 mL of CH2Cl2.  The emulsion was broken by addition of EtOAc.  The organic 
phase was separated, washed with brine, and dried over Na2SO4.  The solution was 
concentrated under reduced pressure, and the residue recrystallized from CH2Cl2 to give 
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the desired product (113 mg, 54%).  Additional material present in mother liquor could 
be recovered if desired.  Material carried on to the next step without characterization.   
NVOC-3-F-4-OMe-DL-phenylalanine cyanomethyl ester (3a).  Compound 2a (66mg, 
0.146 mmol) was dissolved in 1 mL (15.8 mmol) of chloroacetonitrile and 100 µL (0.721 
mmol) of triethylamine was added.  The reaction was allowed to stir at room temperature 
for 28 h.  After evaporating to dryness under high vacuum, the crude material was 
purified by silica gel chromatography eluting with 1:1 EtOAc/hexanes to yield 71.8 mg 
(100%) of the desired product.  1H NMR (300 MHz, CDCl3) δ 7.71 (s, 1H), 6.94 (s, 1H), 
6.93 – 6.83 (m, 3H), 5.57 (d, J = 15.0 Hz, 1H), 5.48 (d, J = 14.7 Hz, 1H), 5.26 (d, J = 8.3 
Hz, 1H), 4.84 (d, J = 15.7 Hz, 1H), 4.70 (d, J = 15.7 Hz, 1H), 4.72 – 4.65 (m, 1H), 3.97 
(s, 3H), 3.95 (s, 3H), 3.87 (s, 3H), 3.18 – 3.01 (m, 2H).  19F NMR (282 MHz, CDCl3) 
δ -134.19 (m).. 
NVOC-3,5-F2-4-OMe-DL-phenylalanine cyanomethyl ester (3b).  Compound 2b (113 
mg, 0.240 mmol) was dissolved in 1 mL (15.8 mmol) of chloroacetonitrile and 150 µL 
(1.08 mmol) of triethylamine was added.  The reaction was allowed to stir at room 
temperature for 16.5 h.  After evaporating to dryness under high vacuum, the crude 
material was purified by silica gel chromatography eluting with 1:1 EtOAc/hexanes to 
yield 115 mg (94%) of the desired product.  1H NMR (300 MHz, DMSO-d6) δ 8.16 (d, J 
= 8.1 Hz, 1H), 7.67 (s, 1H), 7.27 – 6.88 (m, 3H), 5.32 (s, 2H), 5.02 (s, 2H), 4.71 – 4.30 
(m, 1H), 3.86 (br, 6H), 3.33 (s, 3H), 3.05 (dd, J = 13.8, 5.4 Hz, 1H), 2.98 – 2.78 (m, 1H).  
19F NMR (282 MHz, DMSO-d6) δ -129.32 , -129.34.  ESI-MS(+) m/z for 
C22H21F2N3NaO9 found 532.2, calculated 532.1 (M+Na+). 
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dCA- NVOC-3-F-4-OMe-DL-phenylalanine (4a).  Compound 3a (9.3 mg, 0.019 mmol) 
was dissolved in 0.5 mL of dry DMF and added to premixed dCA (5.9 mg, 0.009 mmol) 
and tetrabutylammonium hydroxide (4.2 mg, 0.021 mmol).  The reaction was stirred 
under argon at room temperature for 18 h.  It was diluted with 1:1 MeCN:water and 
purified by reverse phase HPLC running a gradient of 95% to 0% aq. NH4OAc pH 4.5 in 
MeCN to obtain 2.4 mg (24%) of the desired product.  HRMS ES(+) m/z for 
C39H45FN10O21P2 found 1071.2289, calculated 1071.2293 (M+H). 
dCA- NVOC-3,5-F2-4-OMe-DL-phenylalanine (4b).  Compound 3b (10 mg, 0.019 mmol) 
was dissolved in 0.5 mL of dry DMF and added to premixed dCA (5.9 mg, 0.009 mmol) 
and tetrabutylammonium hydroxide (4.2 mg, 0.021 mmol).  The reaction was stirred 
under argon at room temperature for 18 h.  It was diluted with 1:1 MeCN:water and 
purified by reverse phase HPLC running a gradient of 95% to 0% aq. NH4OAc pH 4.5 in 
MeCN to obtain 2.2 mg (22%) of the desired product.  HRMS ES(+) m/z for 
C39H44F2N10O21P2 found 1089.2201, calculated 1089.2199 (M+H). 
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Chapter 4 
 
Preparation of Translationally Competent tRNA by Direct Chemical 
Acylation 
 
Noah H. Duffy and Dennis A. Dougherty 
Division of Chemistry and Chemical Engineering, California Institute of 
Technology, Pasadena, California 91125 
 
 
 
4.1 ABSTRACT 
 
Nonsense codon suppression for unnatural amino acid incorporation requires the 
preparation of a suppressor aminoacyl-tRNA.  Chemical acylation strategies are general, 
but inefficient and arduous. A recent report (J. Am. Chem. Soc. 2007, 129, 15848) 
showed acylation of RNA mediated by lanthanum(III) using amino acid phosphate esters.  
The successful implementation of this methodology to full-length suppressor tRNA is 
described, and it is shown that the derived aminoacyl-tRNA is translationally competent 
in Xenopus oocytes. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Reproduced with modification with permission from Duffy, N. H.; Dougherty, D. A., Preparation of 
Translationally Competent tRNA by Direct Chemical Acylation. Organic Letters 2010, 12, 3776-3779. 
Copyright 2010 American Chemical Society. 
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4.2 INTRODUCTION, RESULTS, AND DISCUSSION 
Structure-function studies using unnatural amino acid mutagenesis provide precision 
beyond that which can be obtained with the 20 natural amino acids.1-3  This is usually 
achieved through nonsense suppression, in which the site of interest is mutated to a stop 
codon, and an aminoacyl-tRNA bearing the appropriate anticodon delivers the unnatural 
amino acid during translation.  The aminoacyl-tRNA is critical to this methodology, and 
several approaches to generating it have been developed.2,4,5  Native aminoacyl-tRNAs 
are generated via reactions of ATP-activated amino acids with the cognate tRNA, 
mediated by the corresponding aminoacyl-tRNA synthetase (aaRS).6  In some cases, the 
natural system can be hijacked to charge an unnatural amino acid onto a tRNA, if the 
difference between the unnatural and cognate amino acids is not large.  Methods for 
generating orthogonal aaRS/tRNA pairs that accept unnatural amino acids have been 
shown to be a viable source of aminoacyl-tRNA.7  Alternatively, amino acids may be 
appended to tRNA using chemical synthesis.  All strategies have particular advantages 
and disadvantages, and the chemical acylation approach is the focus of the present work. 
The standard chemical aminoacylation strategy begins with chemically synthesized 
dinucleotide pdCpA (dCA), which is then acylated with the desired amino acid.4,8 The 
derived aminoacyl-dCA is then enzymatically appended to tRNA via T4 ligase.  This 
method provides maximal flexibility, as virtually any amino acid can be used.  When 
combined with an appropriate expression system, the chemically synthesized aminoacyl-
tRNA does not get recharged by an endogenous aaRS (an intentional aspect of the 
experimental design), and so the aminoacyl-tRNA is a stoichiometric reagent.  Since the 
synthesis of the aminoacyl-tRNA is arduous, the quantity of protein that can be produced 
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using the chemical aminoacylation strategy is limited.  For the most part, the 
methodology has been exploited to study ion channels and neuroreceptors, where the 
extraordinary sensitivity of electrophysiology overcomes the quantity limitation.1 
Scheme 4.1.  La3+ mediated acylation of the 3’ end of tRNA. 
 
 
Tzvetkova and Kluger reported selective acylation of the 3’ end of RNAs through the 
use of La3+ salts and amino acids activated as ethyl phosphate esters (Scheme 4.1).9  We 
will refer to this biomimetic strategy as the La3+/EP  approach.  If direct aminoacylation 
of full length tRNA can produce translationally competent tRNAs, the synthesis of dCA, 
one of the most laborious aspects of the chemical aminoacylation strategy, would become 
unnecessary.  As such, we have evaluated the La3+/EP strategy, focusing on two 
questions: (1) can we optimize the direct acylation of full length, suppressor tRNAs; and 
(2) are the resulting aminoacyl-tRNAs translationally competent in protein synthesis?  In 
particular, our application of nonsense suppression to studies of neuroreceptors and ion 
channels requires expression in a vertebrate cell, the Xenopus laevis oocyte.4  This adds 
additional challenges to the methodology, compared to in vitro protein synthesis 
strategies. 
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Scheme 4.2.  Synthesis of amino acid ethyl phosphates 
 
 
To address these questions, we prepared a variety of amino acids as derivatives 3a–3f 
(Scheme 4.2), in which the carboxylate is activated as an ethyl phosphate, and the amino 
group is protected with NVOC.  This protecting group has been previously established to 
be compatible with the Xenopus oocyte expression system – it is removed 
photochemically before use in translation.4  The amino acid ethyl phosphates (aaEP) were 
prepared by protection of the amino group, followed by coupling of 
bis(tetraethylammonium) ethyl phosphate to the carboxylate using DCC10 (Scheme 4.2).  
As a consequence of our selected protecting groups, the NVOC-amino acids were 
insoluble in CH2Cl2, but readily soluble in THF.  Addition of THF as a co-solvent to 
CH2Cl2 was required to alleviate solubility issues, and a system only using THF was not 
viable because of DCC solubility issues.  Water solubility of the resulting aaEP is an 
important factor in purification of the aaEP as well as later reactivity.  Protection of the 
phenolic OH on tyrosine was not necessary under these reaction conditions for 
preparation of TyrEP (3b).  Tetraethylammonium salts of aaEPs 3a–3f were obtained by 
extraction into water, followed by lyophilization.  The resulting foamy materials were 
used directly without further purification. 
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Before attempting La3+ mediated acylation to tRNA, a preliminary screen of acylation 
of uridine (4) was performed (Scheme 4.3).  Initial conditions were based on literature 
precedent,9 using PheEP (3e).  Reactions were quantified by integration of HPLC or 
LC/MS traces using a UV detector.  Acylation of uridine to form 2’/3’ esters (5e) was 
inefficient (Table 4.1).  Variations in reaction time or temperature (Table 4.1, entry 1–5), 
or the buffer (Table 4.1, entry 9–14) did not significantly improve the yield of 2’/3’ 
esters.  Addition of La3+ to the reaction caused significant precipitation of a solid 
material, and therefore a co-solvent was introduced to alleviate solubility issues 
(Table 4.1, entry 15–23).  Observing the increases in yield by addition of a co-solvent 
lead to further reaction optimization.  In anticipation of optimization experiments using 
tRNA as the substrate, further reactions were run with LysEP (3f) as the amino acid (see 
below).  
Scheme 4.3.  Acylation of uridine using amino acid ethyl phosphates. 
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Table 4.1.  Reaction screen for acylation of uridine (4) using PheEP (3e). 
 
  Applying La3+ mediated acylation conditions to uridine with LysEP (3f) gave 2’/3’ 
esters (5f) in low overall conversion (Table 4.2, entry 46–47).  Initial inclusion of DMSO 
as a co-solvent decreased yield (Table 4.2, entry 40–45), however increasing equivalents 
of LysEP and La3+ while concurrently increasing the %DMSO (v/v) in the reaction lead 
to increased yields (Table 4.2, entry 1–39, Figure 4.1).  Acetonitrile also improved 2’/3’ 
ester yield, but not to the same extent as DMSO.  At high %DMSO (v/v) conditions, 
some acylation of the reaction buffer was detected (by LC/MS); however, under no 
conditions were multiple acylations of uridine detected.  It was reasoned that generation 
of these additional side products would not pose a problem when acylating tRNA, as they 
would be removed during tRNA purification. 
  
PheEP
Entry
Equivalents0
aaEP0/0La3+ Co7solvent% Co7solvent
Reaction0
Time
Reaction0
Temp. Yield Notes
1 1 7 7 200min 250°C 8% 7
2 1 7 7 1900min 250°C 12% 7
3 1 7 7 4500min 250°C 11% 7
4 1 7 7 4500min 420°C 9% 7
5 1 7 7 300min 250°C 5% Change0order0of0addition
6 100EP0/010La 7 7 4650min 250°C 5% 7
7 10EP0/00.660La 7 7 2400min 250°C 3% 7
8 10 7 7 3000min 250°C 11% 7
9 1 7 7 1200min 250°C 4% 10eq.0EPPS0buffer0pH08
10 1 7 7 1100min 250°C 5% 10eq.0EPPS0buffer0pH07.5
11 1 7 7 250min 250°C 6% 10eq.0EPPS0buffer0pH08
12 1 7 7 1700min 250°C 7% 10eq.0MOPS0buffer0pH07.5
13 1 7 7 500min 250°C 11% 7.50eq.0TRIS0buffer0pH08
14 1 7 7 1300min 250°C 0% No0buffer
15 1 50% DMSO 1000min 250°C 22% 7
16 1 25% DMSO 600min 250°C 21% 7
17 1 25% DMSO 400min 250°C 26% 7
18 1 25% MeCN 300min 250°C 20% 7
19 10 25% DMSO 2000min 250°C 27% 7
20 10EP0/00.660La 25% DMSO 2000min 250°C 15% 7
21 100EP0/00.660La 25% DMSO 2000min 250°C 4% 7
22 100EP0/010La 25% DMSO 2000min 250°C 6% 7
23 1 10% DMSO 350min 250°C 16% 7
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Table 4.2.  Reaction screen for acylation of uridine (4) using LysEP (3f). 
   
 
Further increases to beyond ~66 equivalents of LysEP and La3+ were impractical for 
detection of 2’/3’ esters by HPLC and LC/MS, because at this ratio the analytical aliquots 
reached the limit of total material capable of being injected onto the respective instrument 
columns.  Further dilution of the reaction aliquot reduced the observable signal of 2’/3’ 
esters beyond detection. 
  
LysEP
Entry
Equivalents0
aaEP0/0La3+ Co6solvent% Co6solvent
Reaction0
Time
Reaction0
Temp. Yield Notes
24 67 50% DMSO 900min 450°C 57% 6
25 67 20% DMSO 900min 450°C 25% 6
26 20 60% DMSO 900min 250°C 49% 6
27 20 45% DMSO 900min 250°C 42% 6
28 10 60% DMSO 900min 250°C 35% 6
29 10 60% DMSO 900min 450°C 37% 6
30 10 45% DMSO 900min 250°C 32% 6
31 10 45% DMSO 900min 450°C 36% 6
32 10 20% DMSO 900min 250°C 17% 6
33 10 20% DMSO 900min 450°C 16% 6
34 5 60% DMSO 900min 250°C 19% 6
35 5 60% DMSO 900min 450°C 17% 6
36 5 45% DMSO 900min 250°C 21% 6
37 5 45% DMSO 900min 450°C 19% 6
38 5 20% DMSO 900min 250°C 13% 6
39 5 20% DMSO 900min 450°C 11% 6
40 1 60% DMSO 900min 250°C 7% 6
41 1 60% DMSO 900min 450°C 3% 6
42 1 45% DMSO 900min 250°C 6% 6
43 1 45% DMSO 900min 450°C 4% 6
44 1 20% DMSO 900min 250°C 5% 6
45 1 20% DMSO 900min 450°C 3% 6
46 1 6 6 600min 250°C 11% Sonicate0reaction
47 1 6 6 3000min 250°C 12% 6
48 20 60% MeCN 900min 250°C 21% 6
49 1 60% MeCN 900min 250°C 5% 6
50 1 45% MeCN 900min 250°C 4% 6
51 1 20% MeCN 900min 250°C 3% 6
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Figure 4.1. Yield of the acylation of uridine to form 2’/3’ esters of Lys (5f) as a function of equivalents, 
%DMSO (v/v), and reaction temperature. 
 
In their report, Tzvetkova and Kluger detected acylation of RNA by careful selection 
of the amino acid — specifically, a fluorinated amino acid (19F-NMR detection) or a 
dansylated amino acid (fluorescence detection).  Our aaEPs were not selected with these 
detection methods in mind, and therefore we needed a more general method of detecting 
acylation.  Previously our laboratory developed a MALDI-TOF mass spectrometry 
method for detecting enzymatic ligation of a dCA-amino acid to a tRNA transcript 
lacking the 3’-terminal pCpA.11  Runoff transcription of tRNA gave a mixture of tRNA 
lengths (N+1, N+2, etc.) from addition of non-templated nucleotides at the 3’ end.12  
LysEP (3f) was used for reaction screening with tRNA, as the mass of NVOC-BOC-Lys 
acylated tRNA does not coincide with the mass of N+ species (Figure 4.2).  We 
anticipated that with this shift in the MALDI signal, acylated tRNA could be detected 
even if conversion was incomplete.  A report by Kao et al.13 was adapted to tRNA by 
Ethan Van Arnem in the Dougherty lab to generate tRNA with greatly reduced N+ 
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activity from modified DNA oligos (Figure 4.2). Without the interfering signals from N+ 
activity, tRNA generated following this preparation was used exclusively for further 
acylation reaction screens. 
Following the trends established in the uridine acylations, acylations were then applied 
to a full length tRNA (Figure 4.2).  Very large excesses of aaEPs and La3+ with respect to 
the tRNA (>1000 equivalents) were required to detect any acylation in the MALDI mass 
spectra.  Key to the successful application of MALDI was treatment of the reaction 
mixture with the well-known lanthanide chelator diethylenetriamine pentaacetic acid 
(DTPA).14,15  While the standard tRNA precipitation protocols removed most of the 
excess La3+, enough remained (~500 µM, as measured by ICP-MS), presumably strongly 
associated with the tRNA, to disrupt the MALDI.  DTPA application followed by size 
exclusion chromatography resulted in clean samples (≤100 nM La3+). A typical 
microinjection volume of 50 nL exposed oocytes to a negligible ≤5 fmol of La3+.  It 
seems likely that an injection of large amounts of La3+ into the Xenopus oocyte would be 
detrimental to receptor synthesis and/or function, further justifying the DTPA treatment. 
Even though a large excess of aaEP was used, products arising from multiple acylations 
were not detected in the MALDI mass spectra; only unacylated and monoacyled tRNA 
was seen (Figure 4.2).  Our previous work has shown that the aminoacyl-tRNA ionizes 
differently than the free tRNA, and therefore exact quantitation of acylation via MALDI 
is not possible.  Therefore, reference mixtures with known ratios of tRNA:aminoacyl-
tRNA were prepared and evaluated by MALDI (Figure 4.3).  Mass spectra of reaction 
products then allowed us to estimate conversion of tRNA to aminoacyl-tRNA to be 5-
25%. 
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Figure 4.2.  MALDI mass spectra of THG73 74mer or 76mer tRNA prepared by runoff transcription from 
native DNA (top left) or modified oligos (top right) followed by exposure to La3+ mediation acylations 
conditions using LysEP (3f, bottom left) or LeuEP (3a, bottom right).  Observed masses shown, theoretical 
masses in parentheses.  A new peak indicative of monoacylation appears, along with unacylated tRNA.  (*) 
Additional peak at 24,438 m/z present from transcription of tRNA, which remains unaffected by the 
acylation conditions. 
 
The monoacylation detected in the MALDI mass spectra was consistent with, but does 
not prove, the notion that only the 3’ end of the tRNA was acylated.  As further evidence, 
as well as to determine if these La3+/EP derived tRNAs could be used in unnatural amino 
acid mutagenesis, we sought a functional test.  Nonsense suppression has been 
extensively employed to probe the nicotinic acetylcholine receptor (nAChR) expressed in 
Xenopus oocytes, involving hundreds of experiments with scores of unnatural amino 
acids.1,16 The nAChR is a membrane-bound, ligand gated ion channel that can be 
functionally interrogated by whole cell electrophysiology.  Briefly, aminoacyl-tRNA and 
mRNA coding for the nAChR and containing a strategically positioned stop codon are 
microinjected into Xenopus oocytes.  Following an incubation time of 24-48 hours, 
expressed nAChRs are probed by application of acetylcholine (ACh) and measuring the 
resulting current.  Channel function is typically expressed as EC50, the concentration of 
 63 
ACh required to achieve the half-maximal response.  As a negative control, injection of 
unacylated suppressor tRNA produces no measurable current as a result of the 
introduction of the stop codon for nonsense suppression. 
 
Figure 4.3.  MALDI mass spectra of THG73-76mer tRNA mixed with THG73-dCA-NVOC-Trp, in 1:3 
(top left), 1:1 (middle left), and 3:1 (bottom left).  Acylated tRNA signal consistently smaller than 
expected.  MALDI mass spectra of THG73-76mer after exposure to La3+ mediated acylation conditions of 
TyrEP (3b, top right), TrpEP (3c,  middle right), or F1-TrpEP (3d, bottom right) used for nonsense 
suppression experiments.  Observed masses shown, theoretical masses in parentheses. 
 
Initial studies focused on so-called wild type recovery experiments, in which the 
amino acid appended to the suppressor tRNA is the amino acid conventionally found at 
the site where the stop codon was inserted.  This experiment should produce wild type 
receptor, with behaviors indistinguishable from conventionally expressed receptor.  As 
shown in Table 4.3, using three different amino acids (Leu, Tyr, and Trp), two different 
tRNAs (THG7317 and TQOpS’18,19), and two variants of the nAChR (the neuronal 
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(α4)2(β2)3 and the muscle-type (α1)2β1δγ), wild type receptors were prepared.  This 
provides strong evidence that the La3+/EP methodology produces translationally 
competent aminoacyl-tRNAs.  To confirm compatibility with unnatural amino acids, 5-
fluorotryptophan (F1-Trp) was incorporated at the cation-π binding site of the muscle-
type receptor (Trp149 of the α subunit).20 The 4-fold shift in EC50 produced in previous 
studies was recapitulated (Figure 4.4).  These results clearly establish that the aminoacyl-
tRNA derived from the La3+/EP method produced ion channels whose functional 
responses match those of channels produced by the dCA method. 
Table 4.3.  Data for suppression experiments using La3+/EP or dCA methods. 
 Leu Tyr 
receptor α42β23 α12β12δγ 
mutation(s) αL9’A:β119TGA α1Y190TAG 
tRNA TQOpS’ THG73 
acylation method La3+/EP dCA La3+/EP dCA 
oocytes (N) 19 18 26 16 
EC50 (µM) 0.55 ± 0.02 0.47 ± 0.01 52 ± 2 44 ± 2 
mean Imax (µA) 2 ± 2 4 ± 2 1 ± 1 9 ± 8 
mean Imax/ngtRNA (µA/ng)a 0.5 ± 0.3 0.8 ± 0.5 0.6 ± 0.4 1.0 ± 0.5 
 
 Trp F1-Trp 
receptor α12β12δγ α12β12δγ 
mutation(s) α1W149TAG α1W149TAG 
tRNA THG73 THG73 
acylation method La3+/EP dCA La3+/EP dCA 
oocytes (N) 52 15 36 27 
EC50 (µM) 55 ± 2 47 ± 1 230 ± 18 200 ± 9 
mean Imax (µA) 8 ± 8 15 ± 11 3 ± 3 11 ± 5 
mean Imax/ngtRNA (µA/ng)a 2 ± 2 3 ± 2 2 ± 2 0.6 ± 0.4 
 
aImax values normalized to ng of acylated tRNA injected into oocytes.  Acylated tRNA estimated as fraction of total tRNA injected 
based on percent conversion measured by MALDI-MS.  The La3+/EP method yielded 5-25% of total tRNA acylated; the dCA method 
yielded 100% of total tRNA acylated. 
 
A notable difference between the dCA and La3+/EP experiments relates to protein 
yield.  The whole cell maximal currents measured for dCA-derived aminoacyl-tRNAs 
were generally higher than those from La3+/EP-derived tRNAs (Table 4.3).  We 
suspected that this reflects the decreased quantity of aminoacyl-tRNA being injected with 
the La3+/EP method because of the incomplete acylation.  Indeed, when we correct for the 
amount of acylated tRNA injected, the yields of receptor from La3+/EP-derived tRNAs 
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are comparable to dCA-derived (Table 4.3).  It is worth reiterating that control 
experiments show that THG73 and TQOpS’ are not appreciably acylated by an 
endogenous aaRS, and injection of unacylated tRNA yields no meaningful signal.  
Injection of a mixture of acylated and unacylated tRNA from the La3+/EP method 
therefore simply produces an effective dilution of acylated tRNA. 
 
Figure 4.4.  Dose-response curves of mouse muscle nAChR, [α1(W149TAG)]2β1δγ when injected with suppressor 
tRNA.  Source of tRNA indicated. 
 
In summary, we have shown that direct acylation of tRNA is a viable alternative to the 
more labor-intensive dCA methodology.  Although acylation yields are not high, in 
appropriately chosen systems the unacylated tRNA does not interfere with ion channel 
characterization.  The low acylation yield gives rise to a comparable reduction in protein 
expression, suggesting the approach will only be viable for systems that express well in 
the Xenopus oocyte or other cell of choice.  Importantly, ion channels derived from 
aminoacyl-tRNA prepared by the La3+/EP method are functionally indistinguishable from 
channels derived from the dCA method, establishing the viability of the approach for 
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whole-cell expression of proteins.  Further work will seek to improve protein yield by 
improving acylation efficiency, or alternatively by separation and concentration of the 
aminoacyl-tRNA. 
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4.4 METHODS 
4.4.1 Acylation of tRNA.  Acylation reaction conditions as follows: 10-30 µg tRNA (~4-
12 µM), 80 mM HEPES pH 7.5, 15-80 mM amino acid ethyl phosphate, and 15-80 mM 
La(OTf)3 (1 equivalent to aaEP) in a final volume of 100 µL.  Addition of La3+ started the 
reaction and generated insoluble complexes.  The reaction was stirred vigorously at room 
temperature for 30 min.  The reaction was quenched by addition of 50 µL of 300 mM 
diethylenetriamine pentaacetic acid (DTPA) and 1.25 M NH4OAc pH 7.5 (final 
concentrations 100 mM DTPA and 417 mM NH4OAc).  Excess amino acid was extracted 
with 1 volume of 25:24:1 phenol:chloroform:isoamyl alcohol, pH 5.2.  The organic layer 
was then extracted with 0.5 volume of DTPA/NH4OAc quench solution.  The combined 
aqueous solutions were then washed with 1 volume of 24:1 chloroform:isoamyl alcohol.  
tRNA was then precipitated by addition of 3 volumes of ethanol and stored at -20 °C 
overnight.  tRNA was pelleted by centrifugation and dissolved in 1 mM NaOAc pH 4.5, 
followed by removal of co-precipitated DTPA-La3+ using a CHROMA SPIN DEPC-
water gel filtration column (Clontech, Mountain View, CA).  The resulting tRNA 
solution was used directly for MALDI-MS analysis or protein expression. 
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4.4.2 Protein Expression in Xenopus Oocytes.  Mouse muscle α1, β1, δ, and γ; and rat 
neuronal α4 and β2 nAChR cDNA in the pAMV vector was linearized with the 
restriction enzyme Not I.  mRNA was prepared by in vitro transcription using the 
mMessage Machine T7 kit (Ambion, Austin, TX).  Unnatural mutations were introduced 
by the standard Stratagene QuickChange protocol using a TAG or TGA mutation at the 
site of interest.  The α4 subunit contained a known mutation in the M2 transmembrane 
helix (L9’A).  Stage V-VI Xenopus laevis oocytes were injected with mRNA in a 
10:2:1:1 ratio for α12β12δγ or 1:20 for α42β23.  Stoichiometry of α4β2 was confirmed by 
monitoring I-V relationships of acetylcholine-induced currents, as described previously.20  
Each cell was injected with 50 nL of a mixture of mRNA (10-19 ng, typically ~13 ng): 
tRNA (3-42 ng, typically ~27 ng).  Uncharged full length tRNA was injected as a 
negative control. 
4.4.3 Electrophysiology.  Electrophysiology experiments were performed 24-48 hours 
after injection using the OpusXpress 6000A instrument (Axon Instruments, Union City, 
CA) in two-electrode voltage clamp mode at a holding potential of  -60 mV.  The running 
buffer was Ca2+-free ND96 solution (96 mM NaCl, 2 mM KCl, 1 mM MgCl2 and 5 mM 
HEPES, pH 7.5).  Oocytes were superfused with running buffer at 1 mL/min for 30 s 
before application of acetylcholine for 15 s, followed by a 116 s wash with the running 
buffer.  Data were sampled at 125 Hz and filtered at 50 Hz.  Acetylcholine chloride was 
purchased from Sigma-Aldrich/RBI (St. Louis, MO).  Does-response data were obtained 
for ≥ 10 acetylcholine concentrations on ≥ 15 cells.  All EC50 and Hill coefficient values 
were obtained by fitting does-response relations to the Hill equation (Inorm = 1 / [ 1 + 
(EC50/[ACh])n]), and are reported as means ± standard error of the fit.  A detailed error 
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analysis of nonsense suppression experiments reveals data are reproducible to ±50% in 
EC50.21 
4.4.4 Synthesis.  Tetraethylammonium NVOC-leucine ethyl phosphate (3a). A round 
bottom flask was charged with α-NVOC-leucine (170 mg, 0.46 mmol) and N,N’-
dicyclohexylcarbodiimide (94 mg, 0.46 mmol) in 10 mL of dry CH2Cl2.  The reaction 
was allowed to stir for 10 min at room temperature.  A separately prepared solution of 
bis(tetraethylammonium) ethyl phosphate (175 mg, 0.46 mmol) in 10 mL dry CH2Cl2 
was added via syringe.  The reaction was allowed to stir for 4 h at room temperature.  The 
reaction mixture was concentrated and resuspended in 5 mL of CH2Cl2.  Upon filtration, 
the organic solution was extracted three times with 5 mL of water.  Saturated NaCl 
solution was added dropwise to aid in emulsion breaking.  The combined aqueous 
extracts were washed with 5 mL CHCl3 followed by lyophilization.  The resulting solid 
was extracted with CH2Cl2 and filtered.  Concentration of the CH2Cl2 solution gave 182 
mg (66 %) of a yellow foam.  Analytical sample obtained by reverse phase HPLC.  1H 
NMR (300 MHz, DMSO-d6) δ 7.76 (d, J = 8.9 Hz, 1H), 7.68 (s, 1H), 7.17 (s, 1H), 5.34 
(s, 2H), 4.03 – 3.91 (m, 1H), 3.90 (s, 3H), 3.84 (s, 3H), 3.70 (dt, J = 14.3, 7.2 Hz, 2H), 
3.17 (q, J = 7.3 Hz, 8H), 1.72 – 1.58 (m, 1H), 1.54 – 1.45 (m, 2H), 1.18 – 1.08 (m, 12H), 
1.03 (t, J = 7.1 Hz, 3H), 0.85 (dd, J = 12.9, 6.5 Hz, 6H).  13C NMR (126 MHz, CDCl3) δ 
169.69, 169.62, 155.57, 154.01, 147.91, 139.09, 128.76, 109.53, 107.99, 63.35, 61.81, 
61.76, 56.80, 56.43, 53.62, 53.58, 52.59, 41.35, 24.82, 23.08, 21.61, 16.64, 16.58, 7.78.  
HRMS ES (–) m/z for C18H26N2O11P, found 477.1259, calculated 477.1274. 
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Tetraethylammonium N-NVOC-tyrosine ethyl phosphate (3b).  A round bottom flask was 
charged with α-NVOC-tyrosine (150 mg, 0.36 mmol) and N,N’-
dicyclohexylcarbodiimide (147 mg, 0.71 mmol) in 1.5 mL of dry THF and 1 mL of dry 
CH2Cl2.  The reaction was allowed to stir for 4 min at room temperature.  A separately 
prepared solution of bis(tetraethylammonium) ethyl phosphate (91 mg, 0.24 mmol) in 4 
mL dry CH2Cl2 was added via syringe.  The reaction was allowed to stir for 19 h at room 
temperature.  The reaction mixture was filtered, and extracted three times with 5 mL of 
water.  Saturated NaCl solution was added dropwise to aid in emulsion breaking.  The 
combined aqueous extracts were lyophilized.  The resulting solid was extracted with 
acetonitrile and filtered.  Concentration of the acetonitrile solution gave a yellow oil, 92 
mg (63 %).  Analytical sample obtained by reverse phase HPLC.  1H NMR (300 MHz, 
CD3CN) δ 8.93 (br, 1H), 7.69 (s, 1H), 7.07 (d, J = 8.6 Hz, 3H), 6.78 (d, J = 8.5 Hz, 2H), 
6.13 (d, J = 8.5 Hz, 1H), 5.39 (s, 2H), 4.44 – 4.32 (m, 1H), 4.05 – 3.79 (m, J = 12.5, 5.1 
Hz, 8H), 3.18 (q, J = 7.3 Hz, 8H), 3.14 – 3.05 (m, 1H), 2.99 – 2.84 (m, 1H), 1.28 – 1.15 
(m, 15H).  13C NMR (126 MHz, CD3CN) δ 168.88, 168.80, 157.53, 155.99, 154.27, 
147.96, 139.02, 130.28, 128.93, 127.23, 117.50, 115.60, 109.63, 108.09, 62.96, 61.45, 
61.40, 57.13, 56.62, 56.00, 52.24, 52.22, 52.19, 35.89, 16.18, 16.12, 6.93.  31P NMR (121 
MHz, CD3CN) δ -8.52.  HRMS ES (–) m/z for C21H24N2O12P, found 527.1062, calculated 
527.1067. 
Tetraethylammonium NVOC-tryptophan ethyl phosphate (3c).  A round bottom flask was 
charged with α-NVOC-tryptophan (107 mg, 0.24 mmol) and N,N’-
dicyclohexylcarbodiimide (50 mg, 0.24 mmol) in 6 mL of dry THF.  The reaction was 
allowed to stir for 10 min.  A separately prepared solution of bis(tetraethylammonium) 
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ethyl phosphate (93 mg, 0.25 mmol) in 5 mL CH2Cl2 was then added via syringe.  The 
reaction allowed to stir overnight at room temperature.  The reaction mixture was 
concentrated on a rotary evaporator and resuspended in 2.5 mL of CH2Cl2.  Filtration of 
the suspension gave an organic solution that was extracted three times with 2 mL of 
water. Combined aqueous extracts were washed with 2 mL of CHCl3 followed by 
lyophilization to give a yellow foam, 87.9 mg (55%).  Analytical sample obtained by 
reverse phase HPLC.  1H NMR (300 MHz, CDCl3) δ 11.41 (s, 1H), 7.67 (s, 1H), 7.62 – 
7.42 (m, 3H), 7.12 – 6.88 (m, 3H), 5.58 (d, J = 8.2 Hz, 1H), 5.47 (s, 2H), 4.80 – 4.60 (m, 
1H), 4.18 – 4.01 (m, 2H), 3.96 (s, 3H), 3.81 (s, 3H), 3.42 (d, J = 4.6 Hz, 2H), 2.93 (q, J = 
7.3 Hz, 8H), 1.28 (t, J = 7.0 Hz, 3H), 1.01 (t, J = 7.1 Hz, 12H).  13C NMR (75 MHz, 
CDCl3) δ 168.76, 168.63, 155.30, 153.81, 148.02, 139.33, 136.58, 128.41, 128.36, 
125.17, 120.96, 118.74, 117.72, 112.43, 110.09, 108.07, 107.85, 77.45, 77.02, 76.60, 
63.40, 62.13, 62.04, 56.60, 56.39, 52.25, 27.15, 16.68, 16.58, 7.25.  31P NMR (121 MHz, 
CDCl3) δ -7.76.  HRMS ES (–) m/z for C23H25N3O11P, found 550.1229, calculated 
550.1227. 
Tetraethylammonium NVOC-5-fluorotryptophan ethyl phosphate (3d).  A round bottom 
flask was charged with α-NVOC-5-fluorotryptophan (82 mg, 0.18 mmol) and N,N’-
dicyclohexylcarbodiimide (42 mg, 0.20 mmol) in 5 mL of dry THF.  The reaction was 
allowed to stir for 10 min at room temperature.  A separately prepared solution of 
bis(tetraethylammonium) ethyl phosphate (72 mg, 0.19 mmol) in 5 mL dry CH2Cl2 was 
added via syringe.  The reaction was allowed to stir for 24 h at room temperature.  The 
reaction mixture was concentrated and resuspended in 3 mL of CH2Cl2.  Upon filtration, 
the organic solution was extracted three times with 4 mL of water.  Saturated NaCl 
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solution was added dropwise to aid in emulsion breaking.  The combined aqueous 
extracts were lyophilized.  The resulting solid was extracted with CH2Cl2 and filtered.  
Concentration of the CH2Cl2 solution gave a yellow foam 55 mg (44 %).  Analytical 
sample obtained by reverse phase HPLC.  1H NMR (400 MHz, CDCl3) δ 11.71 (s, 1H), 
7.66 (s, 1H), 7.58 (d, J = 2.1 Hz, 1H), 7.53 (dd, J = 8.7, 4.6 Hz, 1H), 7.09 (dd, J = 9.9, 2.3 
Hz, 1H), 6.95 (s, 1H), 6.79 (td, J = 9.1, 2.4 Hz, 1H), 5.59 (d, J = 8.2 Hz, 1H), 5.45 (d, J = 
4.0 Hz, 2H), 4.70 – 4.62 (m, 1H), 4.14 – 4.04 (m, 2H), 3.93 (s, 3H), 3.86 (s, 3H), 3.35 
(ddd, J = 20.0, 14.9, 4.6 Hz, 2H), 2.98 (q, J = 7.3 Hz, 8H), 1.28 (t, J = 7.1 Hz, 3H), 1.03 
(t, J = 7.2 Hz, 12H).  13C NMR (126 MHz, CDCl3) δ 168.75, 168.68, 158.52, 156.67, 
155.32, 153.79, 148.02, 139.42, 133.12, 128.51, 128.44, 128.12, 127.17, 113.18, 113.11, 
110.08, 109.25, 109.04, 108.02, 107.84, 107.81, 102.35, 102.16, 63.52, 62.19, 62.14, 
56.53, 56.37, 52.23, 27.08, 16.62, 16.56, 7.23.  31P NMR (162 MHz, CDCl3) δ -7.83.  
HRMS ES (–) m/z for C23H24N3O11FP, found 568.1110, calculated 568.1133. 
Tetraethylammonium NVOC-phenylalanine ethyl phosphate (3e).  A round bottom flask 
was charged with α-NVOC-phenylalanine (90 mg, 0.22 mmol) and N,N’-
dicyclohexylcarbodiimide (47 mg, 0.23 mmol) in 3 mL of dry THF.  The reaction was 
allowed to stir for 10 min at room temperature.  A separately prepared solution of 
bis(tetraethylammonium) ethyl phosphate (76 mg, 0.20 mmol) in 3 mL of dry THF and 6 
mL of dry CH2Cl2 was added via syringe.  The reaction allowed to stir for 2.75 h at room 
temperature.  The reaction mixture was concentrated and resuspended in 4.5 mL of 
CH2Cl2.  Upon filtration, the organic solution was extracted three times with 5 mL of 
water.  The combined aqueous extracts were lyophilized to give 96.5 mg (76 %).  1H 
NMR (300 MHz, D2O) δ 7.48 (s, H) 7.13 (br, 5H), 6.69 (s, 1H), 5.07 (br, 2H), 4.43 (m, 
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1H), 3.83 (m, 2H), 3.72 (s, 3H), 3.65 (s, 3H), 3.11 (q,  J = 7.3 Hz, 8H), 2.82 (m, 2H), 
1.11 (m, 12H).  31P NMR (121 MHz, D2O) δ -6.14. 
Tetraethylammonium Nα-NVOC-Nε-BOC-lysine ethyl phosphate (3f).  A round bottom 
flask was charged with Nα-NVOC-Nε-BOC-lysine (105 mg, 0.22 mmol) and N,N’-
dicyclohexylcarbodiimide (46 mg, 0.22 mmol) in 10 mL of dry CH2Cl2.  The reaction 
was allowed to stir for 10 min at room temperature.  A separately prepared solution of 
bis(tetraethylammonium) ethyl phosphate (66 mg, 0.17 mmol) in 5 mL of dry CH2Cl2 
was added via syringe.  The reaction was allowed to stir for 2 h at room temperature.  The 
reaction mixture was concentrated and resuspended in 3 mL of CH2Cl2.  Upon filtration, 
the organic solution was extracted with 6 mL of water.  An emulsion formed which was 
broken with 10 mL CH2Cl2 and 1 mL saturated aqueous NaCl.  The organic layer was 
additionally extracted 2x with 10 mL water.  The combined aqueous extracts were 
lyophilized to give a solid mixed with NaCl.  The solid was extracted with chloroform, 
which upon concentration gave 75.2 mg of yellow foam (60 %).  1H NMR (300 MHz, 
CDCl3) δ 7.59 (s, 1H), 7.04 (s, 1H), 6.27 (d J = 8.1 Hz, 1H), 5.38 (m, 2H), 5.02 (br, 1H), 
4.83 (br, 2H), 4.18 (br, 1H), 3.94 (s, 3H), 3.85 (s, 3H), 3.29 (q, J = 7.3 Hz,  8H), 2.98 (br, 
2H), 1.73 (m, 3H), 1.32 (m, 15H), 1.25 (t, J = 7.3 Hz, 12H).  31P NMR (121 MHz, 
CDCl3) δ -7.89.  HRMS TOF-ES (+) m/z for C23H37N3O13P, found 594.2063, calculated 
594.2064. 
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Appendix A1 
Schild Analysis 
 
A1.1 INTRODUCTION 
The concept of a “receptor” was established well before any molecular basis of 
protein-ligand interactions were recognized.1  The action of a ligand-gated ion channel 
(LGIC) can be described by a basic model separating binding and activation steps, and 
this model was also proposed before establishing LGICs as proteins.2  We now regularly 
examine the molecular basis of LGIC function, and agonist-receptor interactions are well 
established.3  Many of these agonist-receptor interactions were determined through a 
functional measure known as the EC50, which is the effective concentration to induce 
half-maximal response.  Measurement of an antagonist-receptor interaction, however, 
requires special consideration.  By definition, an antagonist does not elicit receptor 
activation, and an assay using electrophysiology cannot consist of the antagonist and 
receptor alone.  In Chapter 2, a methodology called Schild analysis was introduced for 
measuring an equilibrium dissociation constant of an antagonist, Kb.4  This appendix 
gives a more thorough discussion of Schild analysis and attempts at its implementation. 
In situations where Schild analysis is applicable (discussed below), the Schild equation 
is as follows: 
 
r =1+ [B]KB
 (1) 
where r is the dose-ratio (or concentration-ratio), [B] is the concentration of antagonist, 
and Kb is the equilibrium binding constant.5  The dose-ratio is the ratio of agonist 
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required to achieve the same signal for a given concentration of antagonist to the agonist 
required in the absence of antagonist.  In this equation, there are no terms for the agonist.  
A series of concentration-response curves can be constructed, each in the presence of a 
constant dose of the antagonist, which should result in shifts of the concentration-
response curve regardless of the nature of the agonist (Figure A1.1a).  From these data, 
the EC50 is usually taken to determine the dose-ratio, r.  For example, suppose a 
hypothetical receptor has an EC50 value of 2 µM for an agonist.  In the presence of 1 µM 
of an antagonist, the EC50 for the agonist for the hypothetical receptor might shift to 10 
µM.  The dose-ratio for 1 µM antagonist is then 10 µM / 2 µM = 5. 
 
Figure A1.1.  Idealized data for Schild analysis.  (a) Parallel shifts of concentration-response curves of an 
ideal receptor in the presence of different concentrations of an antagonist, B.  (b) Plot of log(r-1) derived 
from EC50 data against log([B], µM).  Extrapolation of a linear fit with slope = 1 to the ordinate intercept 
gives the KB.  For these idealized data, the antagonist KB is 10 µM. 
 
Rearranging the Schild equation and taking the logarithm gives: 
 log(r −1) = log([B])− log(KB)  (2) 
A plot of log(r–1) versus log([B]) gives the so-called Schild plot, which is a straight line 
with a slope of 1, and an extrapolation to the intercept gives KB (Figure A1.1b).5 
(a)$ (b)$
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The KB for granisetron, the antagonist examined in Chapter 2, has been determined for 
the serotonin type 3A receptor (5-HT3AR) by radioligand binding.6  Schild analysis, 
though, provides a method for determining the KB of an antagonist by direct functional 
measurements of the receptor.  In addition, the nonsense suppression method of 
introducing an unnatural amino acid reduces the efficiency of transcription.7,8  
Electrophysiological measurements are sensitive enough to easily detect small amounts 
of protein, and coupled with Schild analysis, the KB values of a receptors bearing 
unnatural amino acids appear to be easily obtained. 
In order for Schild analysis to be used, there are requirements that must be met.  
Described by Colquhoun,9 they are as follows: 
(1) The antagonist, B, is a true antagonist that, alone, does not change the 
conformation of the receptor. 
(2) Binding of agonist, A, and antagonist, B, is mutually exclusive at every 
binding site. 
(3) B has the same affinity for every binding site. 
(4) The observed response is the same if the occupancy of each site by A is 
the same, regardless of how many sites are occupied by B. 
(5) Measurements are made at equilibrium. 
 
Systems that do not meet all the requirements can be identified either by the behavior of 
the shifts in the concentration-response curves, or the Schild plot itself.  First, increasing 
concentration of antagonist should shift the concentration-response curve in a parallel 
manner; there should be no large change in Hill slope.  Second, inhibition should be 
surmountable; a sufficiently large dose of agonist should be able to overcome inhibition 
and give the same maximal signal as measured in the absence of antagonist.  An 
antagonist displaying insurmountable inhibition by covalent attachment, allosteric 
inhibition, or for non-equilibrium measurements will display concentration-response 
curves, as shown in Figure A1.2.  Finally, when the Schild plot is constructed, a large 
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deviation of the slope from unity is indicative of the system not meeting all the 
requirements for Schild analysis. 
 
Figure A1.2.  Idealized data showing insurmountable inhibition by an antagonist. 
 
 
In order to implement Schild analysis for the determination of KB values in receptors 
subjected to unnatural amino acid mutagenesis, data were collected by parallel 
multichannel electrophysiology for various combinations of antagonists of the 5-HT3AR. 
A1.2 RESULTS AND DISCUSSION 
In Chapter 2, a Schild analysis of the 5HT3 receptor was attempted with the 
antagonists granisetron and ondansetron.  As shown in Figure A1.3, granisetron and 
ondansetron display insurmountable inhibition of 5-HT3A.  This was attributed to a non-
equilibrium condition related to the slow off rates of the antagonists.  Following this 
conclusion, Schild analysis was attempted for antagonists of lower affinity. 
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Figure A1.3.  Dose-response curves of wild-type 5-HT3A receptor.  Responses to 5-HT with increasing 
concentrations of (a) ondansetron, and (b) granisetron.  Data fit to the Hill equation. 
 
 
The KB at 5-HT3A is 1 nM and 6 nM for granisetron and ondansetron, respectively.10  
Serotonin (5-HT) binds to 5-HT3A with a KD of 110 nM, while the agonist 
5-fluorotryptamine (5-FT) is 830 nM.11  For the mutant 5-HT3A receptor E129Q, 5-FT 
was shown to become an antagonist.12  If the inability to reach full equilibrium 
simultaneously with 5-HT and granisetron/ondansetron was the cause of the apparent 
insurmountable inhibition, a Schild analysis of 5-FT might be possible.  Extended 
incubation of granisetron or ondansetron with 5-HT to reach full equilibrium is not 
possible, as the receptor enters a quiet state in the presence of agonist in a process called 
desensitization.  As shown in Figure A1.4a, inhibition of 5-FT was insurmountable by 
5-HT.  The signal for the four doses of 5-HT at 8.6 µM and 14.3 µM 5-FT indicates a 
plateau without increasing to the level seen for 5-HT in the absence 5-FT. 
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Figure A1.4.  Dose-response curves of (a) E129Q mutant and (b) wild-type 5-HT3A receptors.  Responses 
to (a) 5-HT or (b) mCPBG with increasing concentrations of (a) 5-FT and (b) quinine.  Data fit to the Hill 
equation. 
 
 
While the affinity of 5-FT for 5-HT3A is considerably less than those for granisetron 
or ondansetron, it is possible that a very low affinity antagonist might still be suitable for 
Schild analysis.  The antimalarial drug quinine was reported to inhibit 5-HT3A with an 
affinity of 15 µM, and Schild analysis was applied to 5-HT3A for quinine in Xenopus 
oocytes.13  Attempting to replicate these results, however, was not successful.  As shown 
in Figure A1.4b, inhibition by quinine was insurmountable.  This is in direct contrast to 
the results of Thompson et al.13  The discrepancy of the data in Figure A1.4b and the data 
from Thompson et al.13 is not easily explained.  The agonist used in the appendix was 
meta-chlorophenylbiguanide (mCPBG), but in Schild analysis the identity of the agonist 
should not matter. 
Looking at just the data in this appendix, there are multiple possible explanations as to 
the inapplicability of Schild analysis.  The 5-HT3AR is a pentameric LGIC that has five 
identical orthosteric binding sites (where the agonist binds).  It is known that for the 
(a)$ (b)$
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antagonists examined, the site of action is the orthosteric binding site.  What is unknown, 
however, is what level of occupancy by antagonist versus agonist leads to channel 
inhibition.  In other words, it is unknown if binding of the antagonist at a remote 
orthosteric site is sufficient for inhibition of channel opening, even upon binding of an 
agonist at an unoccupied orthosteric site.  This can also be related to point (1) above. The 
occupation of an orthosteric site by an antagonist could result in a conformational change 
that stabilizes the closed state, in which case the antagonist is not a true antagonist, but 
rather an “inverse agonist.”  While this discussion is speculative, it is clear that whatever 
the true mechanism of inhibition is, it cannot be determined through Schild analysis. 
A1.3 SUMMARY 
While Schild analysis held the possibility of a straightforward method for determining 
the KB of an antagonist for a receptor bearing an unnatural amino acid, its inapplicability 
to the antagonists measured at conventional 5-HT3ARs suggests this is not the case.  
Measurement of KB values using radioligand binding assays is a viable alternative, noting 
that the decreased expression of receptor under nonsense suppression conditions will 
have to be overcome. 
A1.4 METHODS 
Molecular biology, Xenopus oocyte injection, and electrophysiology were described in 
Chapter 2.  In order to measure shifts in the concentration-response curves, a constant 
concentration of the antagonist of interest was applied in all solutions exposed to the 
oocyte including the wash buffer and all agonist solutions.  Concentrations of antagonist 
were measured from lowest to highest.  
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Appendix A2 
The Screening of Ondansetron Analogs 
 
A2.1 INTRODUCTION 
As a validated therapeutic target,1,2 the serotonin type 3A receptor (5-HT3AR) 
continues to be an attractive target for further drug development.  Ondansetron is a 
prototypical 5-HT3A antagonist,3 which is currently used as an antiemetic drug.  
Ondansetron is currently sold as the racemate, and both enantiomers are reported as 
equipotent on rat vagus nerve.3  The adverse effects of racemic ondansetron treatment, 
however, may be a result of the S(–) enantiomer.4  Enantiopure analogs of ondansetron 
may therefore have the potential for improved 5-HT3AR antagonism and possible 
therapeutic applications. 
The Stoltz research group developed an asymmetric allylic alkylation reaction,5 which 
was later applied to lactam substrates.6  Following this line of inquiry, Douglas Duquette 
adapted this reaction for enaminone substrates (Figure A2.1), which upon conversion to 
an indole gave compounds with structural similarities to ondansetron (Figure A2.2).  This 
chemistry allows for exploration of functionality at the stereocenter of ondansetron in a 
stereoselective fashion.  An initial series of compounds synthesized by Douglas Duquette 
was tested for 5-HT3AR antagonism, starting with an exploration of the moiety that 
makes a cation-π interaction with TrpB (Chapter 2).  At this point in testing, enantiopure 
compounds had not been prepared. 
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Figure A2.1.  Example of enaminone allylic alkylation performed by Douglas Duquette. 
 
 
 
 
Figure A2.2.  Structures of ondansetron and analogs prepared for this study.  R1 and R2 defined in 
Table A2.1. 
 
A2.2 RESULTS AND DISCUSSION 
To quickly assess the inhibitory ability of the compounds, a single-point inhibition 
assay was developed.  The assay also measured the whether the compounds cause 
activation of 5-HT3A.  Channel function was determined through three initial EC25 
(1 µM) doses of serotonin (5-HT), where the first, priming dose was excluded from the 
analysis.  The compound of interest as a 10 µM solution was then applied to the channels, 
and allowed to incubate for 1 minute.  During this period, any possible channel activation 
was noted.  Immediately following compound incubation, a mixture of 10 µM of the 
compound and an EC25 dose of 5-HT was applied.  The signal from this co-application 
was compared to the average of the initial EC25 doses of 5-HT to determine the inhibitory 
ability of each compound (Figure A2.3).  The structures of the tested compounds and the 
percentage of signal inhibition of an EC25 dose of 5-HT are shown in Table A2.1.  
Receptor recovery from inhibition was then assessed by two additional doses of 5-HT, 
which were averaged.  A 1 µM dose of ondansetron and a representative solution without 
compound were used as controls. 
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With a 10 µM dose, the compounds tested inhibited an EC25 dose of 5-HT to varying 
degrees.  None of the compounds activated 5-HT3A.  As expected, the methoxyamine 
DCD006 did not inhibit 5-HT signal, as it is likely not protonated at pH 7.4 and cannot 
make a cation-π interaction with TrpB.  It is interesting that the morpholine DCD003 also 
did not inhibit 5-HT signal, especially when compared to the piperidine DCD001.  The 
best inhibition was seen with the smallest of the measured amines (DCD005 and 
DCD007).  When channel recovery was assessed, an increase in signal was noted for all 
 
Figure A2.3.  Average signal of 5-HT3A to 1 µM 5-HT (EC25).  The first column shows the 1 µM 5-HT 
doses applied before compound testing.  The second column shows the co-application of 1 µM 5-HT and 
10 µM compounds, compound-free, or 1 µM ondansetron.  The third column shows the 1 µM 5-HT doses 
applied after compound testing.  Number of oocytes for each measurement and the structure of the tested 
compounds are shown in Table A2.1.  
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compounds tested (Figure A2.3).  This increase in EC25 signal was also noted in the 
compound-free control, and therefore is not potentiation by the tested compounds.  
Inhibition from 1 µM ondansetron was complete and did not wash out over the standard 
2 minute superfusion time. 
  
Table A2.1.  The percent inhibition of the EC25 (1 µM) 5-HT signal from co-application with 10 µM 
solutions of DCDxxx compounds of the 5-HT3AR. 
Compound Structure 
Mouse 5-HT3AR  
10 µM DCDxxx Dose 
% inhibition of 5-HT signal at EC25 (1 µM) 
DCD-001 
 
33	  ±	  6	  
N	  =	  8	  
DCD-002 
 
50	  ±	  2	  
N	  =	  8	  
DCD-003 
 
8	  ±	  4	  
N	  =	  7	  
DCD-004 
 
32	  ±	  4	  
N	  =	  7	  
DCD-005 
 
76	  ±	  2	  
N	  =	  8	  
DCD-006 
 
-­‐3	  ±	  4	  
N	  =	  8	  
DCD-007 
 
84	  ±	  3	  
N	  =	  6	  
Mock  
(0.125% DMSO) – 
7	  ±	  4	  
N	  =	  4	  
Ondansetron 
 
99.57	  ±	  0.01	  
N	  =	  2	  
Compound codes and structures shown.  The number of oocytes for each measurement shown in italics as 
N = x.  
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An IC50 value for the compounds with the best inhibition, DCD005 and DCD007, was 
measured in order to more directly compare with ondansetron.  As described in 
Chapter 2, the IC50 values were determined at 2-fold EC50 5-HT (3.14 µM).  Both 
compounds had IC50 values in the tens of µM, which contrasts with the IC50 value of 
0.87 nM measured for ondansetron (Table A2.2). 
 
Table A2.2.  IC50 data for 5-HT3AR for ondansetron and DCDxxx compounds in response to 5-HT. 
 
 
 
aNumber of oocytes averaged in IC50 determination.  bThe effective concentration for half-maximal 
receptor inhibition.  cThe Hill coefficient, nH, as determined from fitting the Hill equation. 
 
A2.3 SUMMARY 
Data has been collected for new inhibitors of 5-HT3A that have structural similarity to 
ondansetron.  Additional analogs, including enantiopure compounds, will be necessary to 
further develop a structure-activity relationship for development of an inhibitor that can 
rival ondansetron. 
A2.4 METHODS 
Detailed descriptions of oocyte protein expression and electrophysiology methods are 
found in Chapter 2.  DCDxxx compounds were dissolved as stock solutions in aqueous 
DMSO (10-20%) such that diluted oocytes would not be superfused with a solution 
containing more than 0.125% DMSO.  Solubility was aided by conversion to the HCl salt 
by addition of 1 eq. of 1 N aq. HCl. 
  For the single point inhibition assay, oocytes were superfused with running buffer at 
1 mL/min for 30 s before application of EC25 5-HT (1 µM) for 15 s followed by a 116 s 
Antagonist Agonist Na
Ondansetron 21 0.87 ± 0.04 -1.6 ± 0.09
DCD005 7 22 x 103 ± 1 x 103 -2.4 ± 0.2
DCD007 7 18.3 x 103 ± 0.6 x 103 -2.7 ± 0.1
IC50 (nM)b Hillc
5HT
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wash with the running buffer.  This dose was applied three times.  DCDxxx compounds 
or ondansetron was then pre-applied and the oocyte allowed to incubate for 60 s, 
followed by application of a mixture of the antagonist dose with EC25 5-HT (1 µM) for 
15 s.  The oocytes were then washed with the running buffer for 116 s.  Channel recovery 
was determined by application of two doses of EC25 5-HT (1 µM) for 15 s followed by a 
116 s wash with the running buffer. 
IC50 values for DCDxxx compounds were determined at described in Chapter 2. 
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Appendix A3 
Synthesis of 4,7-Difluoroindole 
 
A3.1 INTRODUCTION 
In Chapter 2, the synthesis of 4,7-F2Trp was described using 4,7-difluoroindole.  The 
direct formation of 4,7-difluoroindole from a nitrodifluorobenzene and vinyl magnesium 
bromide was not the initial route examined.  The need for 4,7-difluoroindole provided an 
opportunity to test the utility of the late stage fluorination chemistry reported by Ritter.1  
This appendix reports an alternate synthesis of 4,7-difluoroindole. 
A3.2 RESULTS AND DISCUSSION 
The fluorination conditions reported by Ritter use a tributylarylstannane species to 
participate in a Ag(I) catalytic cycle.1  Starting with commercially available 4-bromo-7-
fluoroindole, a stannylation using Pd(PPh3)4 was performed to generate the 
arylstannane 2 (Scheme A3.1).  Purification of 2 was performed using alumina 
chromatography, as decomposition on silica was observed.  Submitting 2 to fluorination 
conditions did not result in the desired difluoroindole 5.  It was reported that basic 
amines, sulfides, and protic functional groups are incompatible with the reaction 
conditions,1 so it was theorized that the failure to fluorinate was a result of the indole 
nitrogen. 
  
 90 
Scheme A3.1. 
 
 
Arylstannane 2 was protected using di-t-butyl dicarbonate, and then subjected to 
fluorination conditions.  Boc protected difluoroindole 4 was formed; however, 
destannylation to form the monofluoro also occurred.  Separation of the 
monofluoroindole and the difluoroindole was difficult.  The mixture was subjected to 
deprotection using sodium hydroxide in methanol, followed by silica gel purification to 
yield 4,7-difluoroindole 5 as a slightly volatile dark oil. 
A3.3 SUMMARY 
Starting from 4-bromo-7-fluoroindole, the desired 4,7-difluoroindole 5 was prepared 
in 20% overall yield.  The yield could be improved with optimization of the stannylation 
and the Boc deprotection.  Direct formation as described in Chapter 2 was performed in 
18% yield; however, the desired 4,7-difluoroindole required purification from a mixture 
of many side products.  The preparation in this appendix provided authentic material as a 
reference to aid in the isolation from the mixture obtained in Chapter 2. 
A3.4 METHODS 
A3.4.1 Synthesis.  7-fluoro-4-(tributylstannyl)indole (2).  In a dry round bottom flask 
518 mg (2.42 mmol) of 4-bromo-7-fluoroindole was added.  A solution of 140 mg (0.121 
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F
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mmol, 5 mol%) of Pd(PPh3)4 in 10 mL of dry toluene was added to the round bottom 
flask.  Hexa-n-butylditin (1.8 mL, 3.57 mmol) was added via syringe.  The reaction was 
stirred at 100 °C for 19 h under argon.  The reaction was filtered and purified using an 
alumina column running 5% CH2Cl2 in hexanes to 10% CH2Cl2 in hexanes to yield 488 
mg (48%) of a clear to slightly yellow oil.  1H NMR (300 MHz, CD3OD) δ 7.27 (d, J = 
3.1 Hz, 1H), 7.00 (dd, J = 7.6, 5.4 Hz, 1H), 6.80 (dd, J = 12.0, 7.6 Hz, 1H), 6.44 (dd, J = 
3.6, 3.1 Hz, 1H), 1.66 – 1.45 (m, 6H), 1.42 – 1.23 (m, 6H), 1.21 – 1.08 (m, 6H), 0.86 (t, J 
= 7.3 Hz, 9H).  19F NMR (282 MHz, Methanol-d4) δ -131.63 – -144.53 (m). 
7-fluoro-4-(tributylstannyl)-N-(Boc)indole (3).  In a round bottom flask 364 mg (0.858 
mmol) of indole 2 was dissolved in 5 mL of CH2Cl2.  A solution of 289 mg (1.32 mmol) 
of di-t-butyl carbonate and 5.3 mg (0.043 mmol) of DMAP in 5 mL of CH2Cl2 was added 
to the reaction.  The reaction was stirred at room temperature for 2.5 h.  After 
concentration under reduced pressure, the material was dissolved in 10% CH2Cl2 in 
hexanes and passed through an alumina plug to recover 431 mg (96%) of the desired 
product.  1H NMR (300 MHz, CD2Cl2) δ 7.70 (dd, J = 3.7, 0.5 Hz, 1H), 7.29 (dd, J = 7.7, 
4.7 Hz, 1H), 7.02 (dd, J = 13.2, 7.7 Hz, 1H), 6.58 (dd, J = 3.7, 2.1 Hz, 1H), 1.67 (s, 9H), 
1.64 – 1.51 (m, 6H), 1.45 – 1.28 (m, 6H), 1.24 – 1.14 (m, 6H), 0.91 (t, J = 7.3 Hz, 9H).  
19F NMR (282 MHz, CD2Cl2) δ -117.08 – -117.27 (m). 
4,7-difluoro-N-(Boc)indole (4).  Into a round bottom flask, solid silver(I) oxide (10.5 
mg, 0.045 mmol, 5 mol%), sodium triflate (143 mg, 0.829 mmol), sodium bicarbonate 
(142 mg, 1.69 mmol), and Selectfluor (1-chloromethyl-4-fluoro-1,4-diazonia-
bicyclo[2.2.2]octane bis(tetrafluoroborate)) (439 mg, 1.24 mmol) were added.  A solution 
of 431 mg (0.821 mmol) of indole 3 in 20 mL of DMF was added to the reaction.  
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Methanol (167 µL, 4.13 mmol) was added to the reaction, and the flask was immediately 
sealed.  The sealed reaction flask was heated to 65 °C and stirred for 4 h.  The reaction 
was cooled to room temperature and then filtered.  Silica gel chromatography eluting 
with 2% EtOAc in hexanes to 4% EtOAc in hexanes yielded 148 mg of a mixture of the 
desired difluoroindole and monofluoroindole as detected by 19F NMR.  The mixture was 
carried on to the next reaction.  19F NMR (282 MHz,CD2Cl2) δ -121.32 – -122.90 
(m), -128.48 – -129.81 (m). 
4,7-difluoroindole (5).  The mixture 4 was dissolved in 8 mL methanol and 0.1 mL of 
concentrated NaOH was added.  The reaction was stirred at 60 °C for 1 h and then 
concentrated under reduced pressure.  To the concentrated oil was added 10 mL of water 
and 10 mL of CH2Cl2.  The aqueous layer was separated and washed with 1 x 10 mL of 
CH2Cl2.  The combined organics were washed with 1 x 10 mL of brine, dried over 
Na2SO4 and concentrated under reduced pressure.  The crude oil was run down a silica 
column eluting with a gradient starting at 1% EtOAc in hexanes to 10% EtOAc in 
hexanes to give 54 mg (60%) of a volatile dark oil.  H NMR (300 MHz, CDCl3): δ 8.47 
(br, 1H), 7.18 (t, J = 2.8 Hz, 1H), 6.78 (ddd, J = 10.3, 8.6, 3.5 Hz, 1H), 6.71 – 6.60 (m, 
2H). 19F NMR (282 MHz, CDCl3):  δ -124.1 – -129.8 (m), -139.4 – -142.3 (m).  13C 
NMR (126 MHz, CDCl3): δ 152.2 (dd, J = 239, 2.4 Hz), 145.8 (dd, J = 238.6, 3.0 Hz), 
126.0 (dd, J = 15.9, 11.5 Hz), 124.7, 119.9 (dd, J = 24.9, 5.7 Hz), 106.4 (dd, J = 18.9, 8.2 
Hz), 103.9 (dd, J = 18.9 8.2 Hz), 99.8. HRMS EI(+) m/z for C8H5NF2 found 153.0395, 
calculated 153.0390 (M+•). 
A3.5 REFERENCES 
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Appendix A4 
Preparation of Acylated tRNA Through Adenosine 
Phorphoroanhydrides 
 
A4.1 INTRODUCTION 
In Chapter 4, a chemical method for acylation of tRNA was discussed as an alternative 
to acylation of the dinucleotide deoxycytidine-adenosine (dCA, Figure A4.1).  As the 
chemical acylation of tRNA remains a challenging problem, many research labs continue 
to seek new methods.  A publication by the Hecht lab describing the preparation of 
diacylated tRNA implemented a method using adenosine phosphoroanhydrides (AppA) 
shown in Figure A4.1.1  Attachment of both acylated dCA and acylated AppA is 
accomplished using T4 RNA ligase.  The tRNA substrates, however, are of differing 
length: a 74mer is used with dCA and a 75mer is used with AppA.  Use of AppA to 
generate acylated tRNA was explored as an alternative to the use of dCA. 
 
 
Figure A4.1. Structures of nucleotide species for preparation of acylated tRNA. 
A4.2 RESULTS AND DISCUSSION 
The preparation of acylated AppA and its ligation to tRNA was described before the 
use of dCA was described.2  Adenosine mono-phosphate (AMP) was acylated using the 
cyanomethyl ester of nitroveratryl protected tryptophan similarly to previously published 
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procedures (Scheme A4.1).1,3  The tryptophan phosphoroanhydride (AppA-Trp) was 
prepared by coupling to AMP using 1,1’-carbonyldiimidazole following a procedure 
described by Hecht.2  The reaction generated AppA-Trp as a minor component, but 
enough material was synthesized for the examination of the T4 RNA ligase reaction.  
Additional synthesis of AppA-Trp would likely benefit from more modern coupling 
methods.4,5 
Scheme A4.1. 
 
To obtain 75 mer tRNA, a synthetic DNA oligonucleotide for the THG73 tRNA6 was 
purchased from Eurofins Operon Genomics and mixed with a short complementary 
strand for T7 polymerase promoter region (Figure A4.3).7  This oligo contains 2’-OMe 
modifications on the last two bases, and this modification reduces non-templated N+1 
addition at the 3’ end of the tRNA.8,9 
 
O
OH OH
N
N N
N
NH2
N
NN
N
NH2
OOP
OH
O
OH
O P O
OH
O
H
N
O
O
O
O
NO2
O
O
N
H
O
OH OH
N
N N
N
NH2
O P OH
OH
O
N
NN
N
NH2
OOP
OH
O
OH
HO
H
N
O
O
O
O
NO2
O
O
N
NN
N
NH2
OOP
OH
O
OH
HO
OH
NVOC-Trp-CH2CN
N
H
Bu4NOH
AMP
AMP-Trp
(1) 1,1'-carbonyldiimidazole
(2) AMP-Trp
AMP
AppA-Trp
 95 
 
 
 
Figure A4.3.  Sequence of the synthetic oligonucleotides used to transcribe THG75-75mer tRNA.  Bases 
marked (*) contain a 2’-OMe modification. 
 
 
 
Ligation of AppA-Trp to THG73-75mer was attempted using T4 RNA ligase as 
previously described without ATP in the reaction mix.1 Ligation efficiency was 
determined using MALDI-TOF-MS.11  As shown in Figure A4.4, ligation efficiency is 
very low.  The identity of the MALDI peak was confirmed by using this sample in a 
Xenopus oocyte nonsense suppression experiment of the 5-HT3A receptor at W183TAG, 
as described in Chapter 4 (Figure A4.5a).  As a positive suppression control, an acylated 
THG73 derived from dCA was also examined (Figure A4.5b).  No signal was detected in 
response to serotonin (5-HT) when untreated THG73-75mer was used in the suppression 
experiment.  These data indicate tryptophan was selectively incorporated at W183 in 
5-HT3A, and the identity of the small peak in Figure A4.4 is confirmed to be THG73-
76mer-Trp.  The difference in maximal currents measured for the dCA and AppA-Trp 
derived tRNAs are similar to those obtained in Chapter 4, again reiterating the low 
ligation efficiency. 
5’-TAATACGACTCACTATAG-3’
3’-ATTATGCTGAGTGATATCCAAGATATCATATCGCCAATCATGACCCCTGAGATTTAGGGAACTGGACCCAAGCTTAGGGTCATCCTGGCG*G*-5’
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Figure A4.4.  MALDI mass spectra of THG73 75mer (top) or 75mer tRNA after treatment with AppA-Trp 
and T4 RNA ligase (bottom).  Observed masses shown, theoretical masses in parentheses.  
 
 
 
 
Figure A4.5.  Dose-response curves of mouse 5-HT3A, W183TAG when injected with THG73 tRNA 
bearing marked amino acid derived from ligation with T4 RNA ligase and (a) AppA-Trp, or 
(b) dCA-5-F1Trp. 
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A4.3 SUMMARY 
The exact conditions reported by Hecht1 were successful in preparing acylated tRNA 
that can participate in nonsense suppression in Xenopus oocytes.  These results show that 
AppA can be a substrate for T4 RNA ligase; however, ligation efficiency is extremely 
low, especially as compared to the nearly quantitative ligation of dCA by T4 RNA ligase. 
A4.4 METHODS 
Molecular biology, Xenopus oocyte injection, and electrophysiology were described in  
Chapter 2. 
A4.4.1 Synthesis.  AMP-Trp.  In a round bottom flask, 70.7 mg of NVOC-Trp-CH2CN 
(0.146 mmol) and 41.3 mg of AMP•H2O (0.113 mmol) were dissolved in 4 mL of dry 
DMF.  Using a micropipette, 93 µL of 1.54 M tetrabutylammonium hydroxide (0.143 
mmol) was added.  The reaction was stirred at room temperature for 48 h.  AMP-Trp 
isolated by multiple rounds of reverse phase HPLC.  Recovered 24.5 mg (28%).  ESI-
MS(+) m/z for C31H34N8O14P found 773.0, calculated 773.6 (M+H+). 
AppA-Trp.  In a round bottom flask, 54 mg of AMP•H2O (0.148 mmol) and 73.5 mg of 
CDI (0.453) were dissolved in 2.5 mL of dry DMF.  The reaction was allowed to stir at 
room temperature for 15 h.  AMP-Trp (10 mg, 0.013 mmol) was added and the reaction 
allowed to stir an additional 72 h.  AppA-Trp was isolated by multiple rounds of reverse 
phase HPLC to recover 2 mg (14%).  HRMS ES (+) m/z for C108H145N32O49P5, found 
1102.2457, calculated 1102.2452 (M+H). 
A4.4.2 Ligation of tRNA.  Ligation reaction conditions as follows: 35 µg tRNA (~15 
µM), 100 mM HEPES pH 7.5, 41 µM AppA-Trp, 15 mM MgCl2, and 200 units T4 RNA 
ligase in a final volume of 100 µL with 15% DMSO.  The reaction was kept at 37 °C for 
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30 min.  The reaction was quenched by addition of 12.5 µL of 3.0 M NaOAc pH 5.0.  
Protein was extracted away with 1 volume of 25:24:1 phenol:chloroform:isoamyl 
alcohol, pH 5.2.  The organic layer was then extracted with 0.5 volume of NaOAc quench 
solution.  The combined aqueous solutions were then washed with 1 volume of 24:1 
chloroform:isoamyl alcohol.  tRNA was then precipitated by addition of 3 volumes of 
ethanol and stored at -20 °C overnight.  tRNA was pelleted by centrifugation and 
dissolved in 1 mM NaOAc pH 4.5.  The resulting tRNA solution was used directly for 
MALDI-MS analysis or protein expression. 
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